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Total	  hip	  arthroplasty	  (THA)	  and	  total	  knee	  arthroplasty	  (TKA)	  are	  two	  of	  the	  most	  
frequently	  performed	  orthopaedic	  procedures.	  	  As	  the	  prevalence	  of	  diabetes	  mellitus	  
(DM)	  continues	  to	  increase	  the	  burden	  of	  its	  sequelae	  and	  associated	  surgical	  
complications	  has	  also	  increased.	  	  More	  patients	  with	  DM	  are	  candidates	  for	  total	  joint	  
arthroplasty	  (TJA)	  than	  ever	  before.	  	  For	  these	  reasons,	  it	  is	  important	  to	  understand	  the	  
associations	  between	  DM	  and	  the	  rates	  of	  perioperative	  adverse	  events	  in	  patients	  with	  
DM	  who	  will	  undergo	  TJA.	  
	  
The	  American	  College	  of	  Surgeons	  National	  Surgical	  Quality	  Improvement	  Program	  
database	  (ACS	  NSQIP)	  records	  perioperative	  adverse	  events	  and	  patient	  factors	  
including	  demographics	  and	  comorbidities.	  	  Patients	  who	  underwent	  TJA	  between	  2005	  
 and	  2014	  were	  identified	  and	  characterized	  as	  having	  either	  insulin	  dependent	  diabetes	  
mellitus	  (IDDM),	  non-­‐insulin	  dependent	  diabetes	  mellitus	  (NIDDM),	  or	  neither.	  
Multivariate	  Poisson	  regression	  was	  used	  to	  assess	  the	  relative	  risk	  of	  multiple	  adverse	  
events	  in	  the	  initial	  30	  postoperative	  days	  while	  controlling	  for	  demographic	  and	  
comorbid	  factors.	  
	  
A	  total	  of	  71,733	  patients	  who	  underwent	  THA	  were	  identified	  (1,920	  IDDM	  (2.7%),	  
6,305	  NIDDM	  (8.8%),	  and	  63,508	  without	  DM	  (88.5%)),	  and	  114,102	  patients	  who	  
underwent	  TKA	  were	  identified	  (4,881	  IDDM	  (4.3%),	  15,367	  NIDDM	  (13.5%),	  and	  93,854	  
(82.2%)	  without	  DM).	  	  Relative	  to	  patients	  without	  diabetes,	  patients	  with	  NIDDM	  who	  
underwent	  THA	  were	  shown	  to	  be	  at	  an	  increased	  relative	  risk	  for	  3	  of	  17	  adverse	  
events	  studied	  while	  those	  who	  underwent	  TKA	  were	  at	  increased	  risk	  for	  2	  of	  17.	  	  
Patients	  with	  NIDDM	  who	  underwent	  THA	  were	  at	  greater	  risk	  for	  sepsis	  or	  septic	  shock,	  
readmission	  to	  hospital	  within	  30	  days,	  and	  extended	  postoperative	  length	  of	  stay	  (LOS)	  
while	  those	  who	  underwent	  TKA	  were	  at	  greater	  risk	  of	  myocardial	  infarction	  (MI)	  and	  
extended	  postoperative	  length	  of	  stay	  (LOS)	  (greater	  than	  5	  days).	  	  Patients	  with	  IDDM	  
who	  underwent	  THA	  were	  shown	  to	  be	  at	  an	  increased	  relative	  risk	  for	  11	  of	  17	  adverse	  
events	  studied.	  	  These	  were	  death,	  sepsis	  or	  septic	  shock,	  myocardial	  infarction,	  wound-­‐
related	  infection,	  unplanned	  intubation,	  renal	  insufficiency,	  return	  to	  the	  operating	  
room,	  readmission,	  pneumonia,	  urinary	  tract	  infection,	  and	  extended	  LOS.	  	  Similarly,	  
patients	  with	  IDDM	  who	  underwent	  TKA	  were	  found	  to	  be	  at	  an	  increased	  relative	  risk	  
for	  12	  of	  17	  adverse	  events	  studied.	  	  These	  were	  sepsis	  or	  septic	  shock,	  MI,	  renal	  failure,	  
 ventilator	  time	  great	  than	  48	  hours,	  unplanned	  intubation,	  renal	  insufficiency,	  return	  to	  
the	  operating	  room,	  wound	  dehiscence,	  readmission	  to	  hospital	  within	  30	  postoperative	  
days,	  pneumonia,	  urinary	  tract	  infection,	  and	  extended	  LOS.	  
	  
Compared	  to	  patients	  with	  NIDDM,	  patients	  with	  IDDM	  are	  at	  greater	  risk	  for	  many	  
more	  perioperative	  adverse	  events	  relative	  to	  patients	  without	  DM.	  This	  association	  
between	  insulin	  dependence	  and	  risks	  of	  adverse	  events	  after	  TJA	  has	  important	  
implications	  for	  patient	  selection,	  preoperative	  risk	  stratification,	  surgical	  planning,	  
postoperative	  expectations,	  and	  patient	  counseling.	  	  These	  data	  will	  be	  useful	  to	  
medical	  and	  surgical	  teams	  so	  that	  they	  may	  better	  anticipate	  or	  prevent	  these	  adverse	  
events	  in	  these	  at-­‐risk	  populations.	  




ACS	  NSQIP	  DISCLAIMER	  
	  
The	  ACS	  NSQIP	  and	  the	  hospitals	  participating	  in	  the	  ACS	  NSQIP	  are	  the	  source	  of	  the	  
data	  used	  herein;	  they	  have	  not	  verified	  and	  are	  not	  responsible	  for	  the	  statistical	  
validity	  of	  the	  data	  analysis	  or	  the	  conclusions	  derived	  by	  the	  authors.	  	  These	  studies	  do	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 PURPOSE	  
	  
These	  studies	  evaluate	  the	  null	  hypotheses	  that	  patients	  with	  insulin	  dependent	  
diabetes	  mellitus	  (IDDM)	  and	  patients	  with	  non-­‐insulin	  dependent	  diabetes	  mellitus	  
(NIDDM)	  do	  not	  have	  greater	  risks	  of	  perioperative	  adverse	  events	  following	  total	  joint	  
arthroplasty	  (TJA)	  relative	  to	  patients	  without	  diabetes	  mellitus	  (DM).	  
	  
The	  study	  presented	  in	  the	  first	  chapter	  evaluates	  the	  above	  hypotheses	  in	  cohort	  of	  
patients	  who	  underwent	  total	  hip	  arthroplasty	  (THA).	  	  This	  study	  used	  the	  American	  
College	  of	  Surgeons	  National	  Surgical	  Quality	  Improvement	  Program	  (ACS	  NSQIP)	  
database	  between	  the	  years	  2005	  and	  2014	  to	  collect	  this	  cohort.	  	  The	  study	  presented	  
in	  the	  second	  chapter	  evaluates	  the	  same	  hypotheses	  in	  a	  total	  knee	  arthroplasty	  (TKA)	  
cohort	  using	  the	  ACS	  NSQIP	  database.	  
	  
Specifically,	  this	  thesis	  compares	  the	  rates	  of	  the	  following	  adverse	  events	  for	  patients	  
with	  IDDM	  or	  NIDDM	  to	  patients	  without	  DM	  following	  THA	  or	  TKA.	  	  The	  adverse	  events	  
studied	  are:	  death,	  cardiac	  arrest,	  stroke	  or	  cerebrovascular	  accident,	  sepsis	  or	  septic	  
shock,	  myocardial	  infarction,	  renal	  failure,	  thrombotic	  event,	  wound-­‐related	  infection,	  
ventilator	  time	  greater	  than	  48	  hours,	  unplanned	  intubation,	  renal	  insufficiency,	  return	  
to	  the	  operating	  room,	  wound	  dehiscence,	  readmission,	  pneumonia,	  urinary	  tract	  
infection,	  and	  extended	  length	  of	  stay	  (greater	  than	  five	  days)	  for	  patients	  with	  IDDM	  or	  
NIDDM	  to	  patients	  without	  DM	  following	  THA	  or	  TKA.	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INTRODUCTION	  TO	  CHAPTERS	  
	  
Total	  joint	  arthroplasty	  (TJA)	  is	  a	  common	  procedure	  to	  relieve	  pain	  from	  osteoarthritis	  
(OA).	  	  Globally,	  the	  prevalence	  of	  OA	  is	  projected	  to	  continue	  increasing1	  and	  the	  rates	  
of	  total	  hip	  arthroplasty	  (THA)	  and	  total	  knee	  arthroplasty	  (TKA)	  in	  the	  United	  States	  
(US)	  are	  also	  projected	  to	  continue	  to	  increase	  through	  the	  decade.2	  	  Diabetes	  mellitus	  
(DM)	  is	  one	  of	  the	  most	  common	  medical	  morbidities	  among	  candidates	  for	  TJA.	  	  The	  
prevalence	  of	  DM	  in	  the	  TJA	  population	  ranges	  from	  6%	  in	  the	  United	  Kingdom3	  and	  
12%	  in	  Western	  China4	  to	  20%	  in	  New	  York	  City5	  and	  19-­‐20%	  in	  the	  US	  generally,6,7	  and	  
the	  prevalence	  of	  DM	  globally8	  and	  in	  the	  US	  continues	  to	  increase.9	  	  According	  to	  a	  
recent	  study	  of	  the	  National	  Health	  Interview	  Survey,	  the	  lifetime	  risk	  of	  being	  
diagnosed	  with	  DM	  in	  the	  US	  is	  40%	  and	  this	  estimate	  is	  13	  to	  20	  percentage	  points	  
greater	  than	  it	  was	  two	  decades	  previously.10	  	  Likewise,	  a	  study	  from	  the	  Centers	  for	  
Disease	  Control	  and	  Prevention	  that	  uses	  current	  US	  census	  data	  estimates	  that	  the	  
prevalence	  of	  DM	  in	  the	  US	  will	  increase	  from	  14%	  in	  2010	  to	  25-­‐28%	  by	  2050.11	  
	  
The	  associations	  between	  DM,	  obesity,	  and	  OA	  are	  complex.	  	  There	  are	  many	  conditions	  
comorbid	  with	  DM,	  and	  some	  of	  the	  most	  common	  of	  these	  are	  hypertension	  (76%),	  
coronary	  artery	  disease	  (28%),	  renal	  disease	  (18%),	  cerebrovascular	  disease	  (16%),	  
 9	  
diabetic	  eye	  disease	  (15%),	  and	  heart	  failure	  (13%).	  	  OA	  is	  second	  only	  to	  hypertension	  
among	  these	  and	  is	  comorbid	  in	  the	  majority	  of	  patients	  with	  DM	  (55%).12	  	  Obesity	  is	  a	  
known	  risk	  factor	  for	  DM13-­‐17	  and	  obesity	  is	  also	  a	  risk	  factor	  for	  OA18-­‐22	  at	  least	  partly	  
related	  to	  increased	  mechanical	  load23	  but	  also	  due	  to	  other	  non-­‐biomechanical	  factors	  
associated	  with	  obesity.24	  	  Furthermore	  OA	  has	  been	  shown	  to	  be	  a	  barrier	  to	  physical	  
activity	  in	  the	  obese,25	  and	  low	  physical	  activity	  levels	  have	  been	  shown	  to	  be	  correlated	  
with	  risks	  of	  DM.14,26	  	  DM	  itself	  may	  also	  be	  a	  risk	  factor	  for	  OA	  independent	  of	  
obesity,27	  perhaps	  related	  to	  an	  effect	  that	  hyperglycemia	  may	  have	  on	  joint	  tissues	  
including	  collagen.28	  	  Clearly,	  the	  association	  between	  DM	  and	  OA	  is	  multifactorial	  and	  
complex.	  
	  
The	  association	  between	  DM,	  OA,	  and	  TJA	  is	  also	  very	  strong.	  	  The	  Centers	  for	  Disease	  
Control	  and	  Prevention	  has	  reported	  that	  the	  prevalence	  of	  OA	  in	  the	  US	  is	  greater	  in	  
adults	  with	  DM	  (52%)	  compared	  to	  adults	  without	  DM	  (29%).29	  	  	  Furthermore,	  studies	  
have	  found	  that	  patients	  with	  DM	  are	  more	  likely	  to	  undergo	  TJA	  than	  patients	  without	  
DM	  independent	  of	  age	  and	  body	  mass	  index,27	  and	  patients	  with	  DM	  have	  greater	  rates	  
of	  TJA	  than	  patients	  without	  DM	  at	  all	  ages	  younger	  than	  66.30	  	  Overall,	  1	  in	  5	  patients	  
who	  undergo	  TJA	  in	  the	  US	  have	  DM,6,7	  so	  it	  is	  important	  to	  investigate	  how	  DM	  is	  
related	  to	  perioperative	  adverse	  events	  after	  TJA.	  
	  
DM	  is	  defined	  by	  a	  fasting	  glucose	  greater	  than	  or	  equal	  to	  126mg/dl,	  or	  a	  2	  hour	  
glucose	  tolerance	  test	  greater	  than	  200mg/dl,	  or	  a	  random	  glucose	  greater	  than	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200mg/dl,	  or	  a	  glycated	  hemoglobin	  (hemoglobin	  A1c,	  HbA1c)	  value	  greater	  than	  
6.5%.31	  	  DM	  is	  often	  described	  as	  type	  1	  or	  type	  2	  in	  non-­‐gestational	  individuals.	  	  The	  
pathogenesis	  of	  DM	  type	  1	  is	  related	  to	  autoimmune	  destruction	  of	  the	  insulin	  secreting	  
beta	  cells	  of	  the	  pancreas,32	  and	  the	  pathogenesis	  of	  DM	  type	  2	  is	  related	  to	  acquired	  
insulin	  resistance.	  	  Individuals	  with	  DM	  type	  1	  are	  always	  insulin	  dependent.	  	  DM	  type	  2	  
can	  be	  managed	  with	  lifestyle	  modifications	  or	  oral	  hypoglycemic	  agents,	  but	  patients	  
with	  recalcitrant	  disease	  may	  become	  insulin	  dependent.32,33	  	  This	  thesis	  categorizes	  
patients	  with	  DM	  by	  pharmacologic	  treatment	  regimen.	  	  For	  the	  purposes	  of	  this	  thesis,	  
patients	  with	  IDDM	  are	  any	  patients	  who	  use	  daily	  insulin	  therapy	  to	  control	  
hyperglycemia,	  and	  patients	  with	  NIDDM	  are	  patients	  who	  use	  pharmacologic	  agents	  
other	  than	  insulin	  to	  control	  hyperglycemia.	  	  For	  the	  purposes	  of	  this	  thesis,	  patients	  
without	  DM	  either	  do	  not	  have	  diabetes	  or	  use	  diet	  and	  lifestyle	  modifications	  alone	  to	  
control	  hyperglycemia.	  
	  
Although	  numerous	  recent	  studies	  have	  reported	  an	  association	  between	  DM	  and	  
adverse	  events	  following	  TJA,4,6,7,34-­‐52	  relatively	  few	  studies	  have	  investigated	  
associations	  between	  these	  adverse	  events	  and	  identifiable	  subpopulations	  of	  patients	  
with	  DM	  such	  as	  patients	  with	  DM	  type	  1	  versus	  DM	  type	  253-­‐55	  or	  patients	  with	  insulin	  
dependent	  diabetes	  mellitus	  (IDDM)	  versus	  non-­‐insulin	  dependent	  diabetes	  mellitus	  
(NIDDM).53,55-­‐57	  	  A	  few	  studies	  have	  found	  that	  patients	  who	  use	  insulin	  are	  at	  greater	  
risk	  for	  particular	  perioperative	  adverse	  events	  –	  most	  notably	  cardiac	  complications	  
after	  elective	  major	  noncardiac	  surgery58	  –	  and	  one	  surgical	  risk	  calculator	  uses	  insulin	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dependence	  as	  one	  of	  many	  risk	  factors	  to	  compute	  the	  absolute	  risks	  of	  particular	  
adverse	  events,59	  but	  no	  studies	  have	  found	  that	  patients	  with	  IDDM	  are	  at	  relatively	  
greater	  risk	  for	  particular	  adverse	  events	  other	  than	  infection57	  after	  TJA.	  
	  
Whether	  patients	  with	  DM	  undergo	  THA	  or	  TKA,	  it	  is	  important	  to	  determine	  whether	  
particular	  subpopulations	  are	  at	  greater	  risk	  for	  adverse	  events,	  and	  determining	  the	  
particular	  adverse	  events	  for	  which	  they	  are	  at	  risk	  is	  also	  important.	  	  Although	  glycemic	  
control	  as	  measured	  by	  glycated	  hemoglobin	  and	  perioperative	  blood	  glucose	  as	  
measured	  by	  postoperative	  blood	  glucose	  level	  are	  well	  recognized	  risk	  factors	  for	  
adverse	  events,60	  the	  association	  between	  insulin	  dependence	  and	  the	  risks	  of	  adverse	  
events	  has	  not	  been	  well	  appreciated.	  	  This	  information	  will	  be	  useful	  for	  patient	  
counseling	  and	  expectations,	  preoperative	  risk	  stratification,	  and	  postoperative	  
management.	  	  Identifying	  particular	  adverse	  events	  for	  which	  subpopulations	  are	  at	  
greater	  risk	  could	  also	  encourage	  the	  implementation	  of	  appropriate	  preventative	  and	  
monitoring	  measures.	  
	  
Furthermore,	  it	  has	  been	  found	  that	  patients	  with	  DM	  incur	  higher	  resource	  utilization	  
and	  costs	  following	  TJA	  than	  patients	  without	  DM61	  at	  least	  partly	  due	  to	  their	  greater	  
risk	  of	  postoperative	  adverse	  events,	  and	  some	  authors	  suggest	  that	  if	  providing	  TJA	  for	  
patients	  with	  DM	  is	  not	  reimbursed	  at	  a	  greater	  rate	  than	  for	  patients	  without	  DM	  than	  
a	  disparity	  in	  care	  may	  develop.7	  	  Likewise,	  it	  may	  be	  known	  or	  assumed	  by	  some	  
providers	  that	  particular	  subpopulations	  of	  patients	  with	  DM	  will	  incur	  greater	  costs	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than	  others,	  and	  for	  this	  reason	  identifying	  the	  particular	  adverse	  events	  for	  which	  
particular	  subpopulations	  are	  at	  risk	  could	  contribute	  to	  amelioration	  of	  disparities	  in	  
provision	  of	  TJA.	  
	  
The	  American	  College	  of	  Surgeons	  National	  Surgical	  Quality	  Improvement	  Program	  (ACS	  
NSQIP)	  database	  is	  uniquely	  useful	  for	  investigating	  these	  associations.	  	  In	  general,	  the	  
statistical	  power	  afforded	  by	  the	  large	  sample	  size	  of	  national	  databases	  is	  helpful	  for	  
investigating	  infrequent	  events	  and	  rare	  patient	  populations.	  	  ACS	  NSQIP	  differs	  from	  
many	  national	  databases	  because	  it	  tracks	  the	  occurrence	  of	  adverse	  events	  that	  occur	  
up	  to	  30	  days	  following	  hospital	  discharge,	  and	  it	  is	  unique	  among	  databases	  with	  
outpatient	  follow-­‐up	  because	  the	  data	  included	  in	  ACS	  NSQIP	  is	  gathered	  by	  specially	  
trained	  medical	  professionals.	  	  In	  contrast	  to	  administrative	  databases	  that	  are	  based	  on	  
reimbursement	  claims	  and	  have	  been	  shown	  to	  be	  limited,62	  inconsistent,63	  and	  fraught	  
with	  errors,64	  ACS	  NSQIP	  data	  are	  chart-­‐abstracted	  and	  prospectively	  collected,	  and	  
high-­‐quality	  data	  is	  ensured	  by	  routine	  auditing.	  	  This	  is	  demonstrated	  by	  an	  agreement	  
rate	  between	  clinical	  reviewers	  of	  greater	  than	  98%.65	  	  This	  reliability	  and	  internal	  
validity	  is	  particularly	  important	  for	  studies	  that	  define	  cohort	  subpopulations	  based	  
upon	  clinical	  parameters.	  	  
	  
For	  the	  reasons	  outlined	  above,	  this	  study	  will	  use	  the	  ACS	  NSQIP	  database	  to	  compare	  
the	  adverse	  event	  rates	  of	  patients	  without	  DM	  to	  patients	  with	  IDDM	  or	  NIDDM	  after	  
THA	  and	  after	  TKA.	  	  THA	  and	  TKA	  will	  be	  treated	  independently.	  	  THA	  will	  be	  considered	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in	  the	  first	  chapter,	  and	  in	  the	  second	  chapter	  TKA	  will	  be	  considered	  in	  a	  similar	  
manner.	  	  These	  chapters	  will	  be	  organized	  as	  if	  they	  were	  distinct	  manuscripts	  meant	  for	  
publication	  in	  a	  peer-­‐reviewed	  journal,	  and	  an	  additional	  conclusion	  section	  will	  be	  
added	  to	  summarize	  the	  thesis.	  






COMPARISON	  OF	  PERIOPERATIVE	  ADVERSE	  EVENT	  RATES	  FOLLOWING	  TOTAL	  HIP	  
ARTHROPLASTY	  IN	  PATIENTS	  WITH	  DIABETES:	  INSULIN	  DEPENDENCE	  MAKES	  A	  
DIFFERENCE.	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Background	  –	  Total	  hip	  arthroplasty	  (THA)	  is	  one	  of	  the	  most	  frequently	  performed	  
orthopaedic	  procedures.	  	  As	  the	  prevalence	  of	  diabetes	  mellitus	  (DM)	  continues	  to	  
increase	  the	  burden	  of	  its	  sequelae	  and	  associated	  surgical	  complications	  have	  also	  
increased.	  	  For	  these	  reasons,	  it	  is	  important	  to	  understand	  the	  associations	  between	  
DM	  and	  the	  rates	  of	  perioperative	  adverse	  events	  in	  patients	  with	  DM	  who	  will	  undergo	  
THA.	  
	  
Methods	  –	  The	  American	  College	  of	  Surgeons	  National	  Surgical	  Quality	  Improvement	  
Program	  (ACS	  NSQIP)	  database	  records	  perioperative	  adverse	  events	  as	  well	  as	  patient	  
factors	  including	  demographics	  and	  comorbidities.	  	  Patients	  who	  underwent	  THA	  
between	  2005	  and	  2014	  were	  identified	  and	  characterized	  as	  having	  insulin	  dependent	  
diabetes	  mellitus	  (IDDM),	  non-­‐insulin	  dependent	  diabetes	  mellitus	  (NIDDM),	  or	  neither.	  	  
Multivariate	  Poisson	  regression	  was	  used	  to	  assess	  the	  relative	  risk	  of	  multiple	  adverse	  




Results	  –	  A	  total	  of	  71,733	  patients	  who	  underwent	  THA	  were	  identified	  (1,920	  IDDM,	  
6,305	  NIDDM,	  and	  63,508	  without	  DM).	  	  Relative	  to	  patients	  without	  diabetes,	  patients	  
with	  NIDDM	  were	  at	  an	  increased	  relative	  risk	  for	  3	  of	  17	  adverse	  events	  studied.	  	  These	  
were	  sepsis	  or	  septic	  shock,	  readmission	  to	  hospital	  within	  30	  days,	  and	  extended	  
postoperative	  length	  of	  stay	  (LOS)	  (greater	  than	  5	  days).	  	  Patients	  with	  IDDM	  were	  at	  an	  
increased	  relative	  risk	  for	  11	  of	  17	  adverse	  events	  studied.	  	  These	  included	  death,	  sepsis	  
or	  septic	  shock,	  myocardial	  infarction,	  wound-­‐related	  infection,	  unplanned	  intubation,	  
renal	  insufficiency,	  return	  to	  the	  operating	  room,	  readmission,	  pneumonia,	  urinary	  tract	  
infection,	  and	  extended	  LOS.	  	  Patients	  with	  IDDM	  and	  NIDDM	  were	  both	  at	  greater	  risk	  
for	  sepsis	  or	  septic	  shock,	  readmission,	  and	  extended	  LOS.	  	  Patients	  with	  IDDM	  were	  at	  
greater	  risk	  for	  all	  of	  these	  adverse	  events	  (sepsis	  or	  septic	  shock:	  relative	  risk	  [RR]	  =	  
3.53	  versus	  1.90,	  for	  IDDM	  and	  NIDDM	  respectively,	  readmission:	  RR	  =	  2.11	  vs.	  1.28,	  and	  
extended	  LOS:	  RR	  =	  2.26	  vs.	  1.35).	  
	  
Conclusions	  –	  Compared	  to	  patients	  with	  NIDDM,	  patients	  with	  IDDM	  are	  at	  greater	  risk	  
for	  many	  more	  perioperative	  adverse	  events	  relative	  to	  patients	  without	  diabetes.	  	  
These	  findings	  have	  important	  implications	  for	  patient	  selection,	  preoperative	  risk	  
stratification,	  and	  postoperative	  expectations.	  







The	  associations	  between	  diabetes	  mellitus	  (DM)	  and	  surgical	  outcomes	  is	  being	  
scrutinized	  to	  a	  greater	  degree	  as	  the	  prevalence	  of	  DM	  increases	  in	  the	  US.9-­‐11	  	  The	  
correlation	  between	  DM	  and	  risks	  of	  complications	  following	  many	  orthopaedic	  
procedures	  has	  been	  well	  established.55,61,66,67	  	  In	  regard	  to	  total	  hip	  arthroplasty	  (THA),	  
previous	  retrospective	  studies	  have	  shown	  that	  patients	  with	  DM	  have	  a	  greater	  risk	  of	  
infection	  of	  the	  surgical	  site,	  urinary	  tract,	  or	  lower	  respiratory	  tract,38	  and	  have	  greater	  
risks	  of	  periprosthetic	  joint	  infection,39,40	  or	  any	  surgical	  site	  infection.41	  	  And	  patients	  
with	  DM	  are	  also	  at	  greater	  risk	  for	  perioperative	  acute	  myocardial	  infarction,36	  or	  
readmission,37,42,43	  or	  for	  developing	  peripheral	  arterial	  disease,34	  or	  persistent	  pain	  in	  
the	  operated	  joint,35	  or	  for	  any	  one	  of	  a	  number	  of	  complications.44	  	  Additionally,	  
patients	  with	  DM	  have	  been	  shown	  to	  stay	  longer	  in	  the	  hospital	  after	  THA68	  and	  to	  
incur	  higher	  resource	  utilization	  and	  costs	  following	  total	  joint	  arthroplasty.61	  	  However,	  
these	  studies	  have	  generally	  categorized	  patients	  as	  either	  diabetic	  or	  not	  diabetic	  and	  
have	  not	  distinguished	  between	  identifiable	  subpopulations	  of	  patients	  with	  DM.	  	  	  
	  
Due	  to	  their	  large	  sample	  sizes,	  national	  databases	  and	  registries	  are	  particularly	  
effective	  for	  the	  analysis	  of	  rare	  adverse	  events	  and	  particular	  subpopulations.	  	  Among	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available	  databases	  The	  American	  College	  of	  Surgeons	  National	  Surgical	  Quality	  
Improvement	  Program	  (ACS	  NSQIP)	  database	  is	  particularly	  useful	  for	  comparing	  
adverse	  event	  rates	  because	  it	  includes	  high-­‐quality,	  chart-­‐abstracted	  data	  that	  is	  
collected	  for	  30	  days	  postoperatively	  regardless	  of	  hospital	  discharge.31,69	  	  For	  example,	  
a	  recent	  study	  of	  perioperative	  adverse	  events	  after	  lumbar	  fusion	  found	  that	  patients	  
with	  insulin	  dependent	  diabetes	  mellitus	  (IDDM)	  were	  at	  increased	  risk	  for	  many	  more	  
perioperative	  adverse	  events	  than	  patients	  with	  non-­‐insulin	  dependent	  diabetes	  
mellitus	  (NIDDM).66	  
	  
There	  is	  one	  prior	  study	  that	  used	  the	  ACS	  NSQIP	  database	  to	  investigate	  the	  association	  
of	  IDDM	  and	  NIDDM	  on	  perioperative	  adverse	  events	  in	  the	  total	  joint	  population.	  	  That	  
study	  used	  data	  collected	  between	  2005	  and	  2011.	  	  That	  study	  considered	  total	  knee	  
arthroplasty	  patients	  together	  with	  THA	  patients	  and	  found	  that	  patients	  with	  IDDM	  
were	  at	  greater	  risk	  for	  infection	  relative	  to	  patients	  without	  DM	  (7%	  versus	  5%)	  and	  
they	  were	  also	  at	  greater	  risk	  for	  any	  “medical	  complication”57	  which	  is	  a	  composite	  of	  
many	  adverse	  events.	  	  However,	  that	  analysis	  did	  not	  find	  that	  patients	  with	  IDDM	  were	  
at	  greater	  risk	  for	  any	  particular	  complications	  other	  than	  infection	  relative	  to	  patients	  
without	  DM.	  	  Since	  that	  study	  the	  number	  of	  THA	  cases	  available	  in	  the	  ACS	  NSQIP	  
database	  has	  more	  than	  quadrupled	  (16,392	  vs.	  71,733	  patients).	  	  The	  increased	  
statistical	  power	  afforded	  by	  this	  large	  sample	  size	  allows	  this	  study	  to	  analyze	  the	  THA	  
population	  in	  isolation	  and	  to	  investigate	  associations	  that	  were	  not	  initially	  apparent.	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This	  study	  will	  for	  the	  first	  time	  identify	  the	  particular	  medical	  complications	  for	  which	  
patients	  with	  IDDM	  are	  at	  risk.	  
	  
This	  study	  assesses	  the	  relative	  risks	  of	  perioperative	  adverse	  events	  after	  THA	  in	  
patients	  with	  IDDM	  and	  NIDDM	  relative	  to	  patients	  without	  DM.	  	  This	  information	  will	  
be	  useful	  for	  patient	  selection,	  postoperative	  surveillance,	  and	  refinement	  of	  risk	  
stratification.	  	  





MATERIALS	  &	  METHODS	  
	  
This	  study	  used	  the	  ACS	  NSQIP	  data	  collected	  between	  the	  years	  2005	  and	  2014.	  	  
Current	  Procedural	  Terminology	  code	  27447	  was	  used	  to	  identify	  patients	  who	  
underwent	  primary	  THA.	  	  Perioperative	  adverse	  events	  are	  tracked	  during	  the	  entire	  30	  
day	  postoperative	  period	  regardless	  of	  hospital	  discharge.	  	  The	  database	  also	  records	  
demographic	  variables	  including	  patient	  age,	  sex,	  height,	  weight,	  and	  smoking	  status	  
among	  other	  comorbidities.	  	  Body	  mass	  index	  (BMI)	  was	  calculated	  from	  patient	  height	  
and	  weight.	  	  The	  Human	  Investigation	  Committee	  at	  our	  institution	  approved	  this	  study.	  
	  
For	  the	  purpose	  of	  controlling	  for	  confounding	  comorbidities,	  a	  modified	  version	  of	  the	  
Charlson	  comorbidity	  index	  (CCI)70	  that	  has	  been	  adapted	  to	  the	  ACS	  NSQIP	  database71	  
was	  used	  to	  categorize	  patient	  comorbidity	  burden.	  	  Studies	  have	  demonstrated	  that	  
this	  modified	  CCI	  predicts	  similar	  outcomes	  as	  the	  original	  CCI.72,73	  	  The	  comorbidities	  
used	  to	  determine	  the	  modified	  CCI	  include	  (followed	  by	  their	  CCI	  point	  values):	  
myocardial	  infarction	  within	  the	  six	  months	  prior	  to	  surgery	  (1),	  congestive	  heart	  failure	  
(1),	  peripheral	  vascular	  disease	  or	  rest	  pain	  (1),	  any	  history	  of	  transient	  ischemic	  attack	  
or	  cerebrovascular	  accident	  (1),	  chronic	  obstructive	  pulmonary	  disease	  (1),	  diabetes	  
mellitus	  (1),	  hemiplegia	  (2),	  end	  stage	  renal	  disease	  (2),	  ascites	  or	  esophageal	  varices	  (3),	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and	  disseminated	  cancer	  (6).	  	  To	  calculate	  the	  CCI	  for	  a	  given	  case	  these	  point	  values	  are	  
summed	  and	  an	  additional	  point	  is	  added	  for	  each	  age	  decade	  older	  than	  age	  40.	  	  
Although	  DM	  is	  included	  as	  a	  comorbid	  condition	  in	  the	  original	  CCI,	  it	  was	  removed	  
from	  the	  modified	  CCI	  calculation	  for	  this	  study	  because	  DM	  is	  the	  comorbidity	  that	  this	  
study	  evaluates.	  
	  
The	  ACS	  NSQIP	  database	  records	  individual	  adverse	  events	  during	  the	  first	  30	  
postoperative	  days.	  A	  prior	  study	  from	  our	  group	  asked	  orthopaedic	  surgeons	  at	  
multiple	  institutions	  to	  weight	  each	  of	  these	  complications	  relative	  to	  a	  single	  patient’s	  
death.	  	  In	  order	  of	  severity	  weight	  relative	  to	  death74	  these	  adverse	  events	  are	  (weight):	  
death	  (1),	  cardiac	  arrest	  requiring	  cardiopulmonary	  resuscitation	  (0.151),	  stroke	  or	  
cerebrovascular	  accident	  (0.010),	  septic	  shock	  (0.087),	  myocardial	  infarction	  (0.042),	  
acute	  renal	  failure	  (0.040),	  pulmonary	  embolism	  (0.030),	  sepsis	  (0.018),	  organ	  space	  
infection	  (0.018),	  ventilator	  time	  greater	  than	  48	  hours	  (0.015),	  deep	  surgical	  site	  
infection	  (0.015),	  unplanned	  intubation	  (0.014),	  renal	  insufficiency	  (0.009),	  return	  to	  the	  
operating	  room	  (0.009),	  superficial	  surgical	  site	  infection	  (0.007),	  deep	  vein	  thrombosis	  
(0.006),	  wound	  dehiscence	  (0.006),	  readmission	  to	  hospital	  (0.006),	  pneumonia	  (0.006),	  
and	  urinary	  tract	  infection	  (0.003).	  	  In	  this	  study,	  pulmonary	  embolism	  and	  deep	  vein	  
thrombosis	  were	  considered	  together	  as	  “thrombotic	  events,”	  superficial	  surgical	  site	  
infection,	  deep	  wound	  infection,	  and	  organ	  space	  infection	  were	  considered	  together	  as	  
a	  “wound-­‐related	  infection,”	  and	  sepsis	  and	  septic	  shock	  were	  also	  considered	  together.	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Postoperative	  length	  of	  stay	  (LOS)	  and	  readmission	  are	  also	  directly	  reported	  in	  the	  ACS	  
NSQIP	  database.	  	  LOS	  is	  defined	  as	  the	  number	  of	  days	  from	  the	  operation	  date	  until	  
discharge.	  	  Readmission	  is	  defined	  as	  any	  admission	  for	  any	  reason	  that	  occurs	  after	  
discharge	  and	  within	  30	  days	  of	  surgery.	  	  While	  most	  postoperative	  variables	  in	  the	  ACS	  
NSQIP	  database	  are	  only	  reported	  if	  they	  occur	  within	  the	  first	  30	  days,	  postoperative	  
LOS	  is	  reported	  beyond	  30	  days.	  	  However,	  in	  order	  to	  limit	  the	  influence	  of	  outliers	  this	  
study	  considered	  patients	  with	  LOS	  longer	  than	  30	  days	  to	  have	  had	  LOS	  equal	  to	  30	  
days.	  	  LOS	  was	  considered	  to	  be	  extended	  if	  the	  stay	  lasted	  longer	  than	  one	  standard	  
deviation	  (2.1	  days)	  longer	  than	  the	  mean	  (3.0	  days)	  of	  all	  hospital	  stays	  in	  the	  cohort.	  	  
However,	  ACS	  NSQIP	  records	  LOS	  in	  terms	  of	  whole	  numbers.	  	  For	  this	  reason,	  any	  LOS	  
longer	  than	  5	  days	  was	  considered	  to	  be	  extended.	  	  	  
	  
The	  occurrence	  of	  readmission	  within	  30	  days	  of	  surgery	  is	  reported	  in	  the	  ACS	  NSQIP	  
database	  for	  cases	  that	  occurred	  in	  2011	  or	  later,	  but	  it	  is	  not	  reported	  for	  earlier	  cases.	  	  
Hence,	  the	  analysis	  of	  readmission	  includes	  64,141	  of	  71,733	  cases,	  representing	  89.4%	  
of	  all	  cases	  included	  in	  this	  study.	  
	  
In	  the	  ACS	  NSQIP	  database	  diabetes	  status	  can	  be	  recorded	  one	  of	  three	  ways.	  	  There	  
are	  patients	  who	  require	  daily	  insulin	  therapy	  to	  treat	  their	  diabetes	  (IDDM),	  those	  who	  
use	  non-­‐insulin	  pharmacologic	  agents	  (NIDDM),	  and	  patients	  who	  do	  not	  have	  DM.	  
Patients	  without	  DM	  either	  do	  not	  have	  insulin	  resistance	  or	  hyperglycemia	  or	  are	  using	  
dietary	  modifications	  alone	  to	  control	  hyperglycemia.	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Statistical	  analyses	  were	  performed	  using	  STATA	  version	  13	  (StataCorp	  LP,	  College	  
Station,	  TX).	  	  Statistical	  significance	  was	  set	  at	  a	  2-­‐sided	  alpha	  level	  of	  0.05,	  but	  the	  
chance	  of	  finding	  one	  or	  more	  spurious	  significant	  differences	  in	  17	  tests	  at	  that	  alpha	  
level	  is	  58.2%.	  	  For	  this	  reason	  the	  level	  of	  significance	  for	  comparisons	  of	  adverse	  event	  
rates	  for	  each	  of	  17	  adverse	  events	  was	  adjusted	  to	  0.003	  according	  to	  Bonferroni’s	  
correction.75	  	  Likewise,	  instead	  of	  reporting	  95%	  confidence	  intervals	  of	  these	  relative	  
risks,	  99.7%	  confidence	  intervals	  are	  reported	  in	  this	  study.	  	  Demographics	  were	  
compared	  between	  patients	  with	  NIDDM,	  patients	  with	  IDDM,	  and	  those	  without	  DM	  
using	  Pearson	  chi-­‐squared	  tests.	  	  	  
	  
Adverse	  event	  rates	  were	  compared	  between	  patients	  with	  NIDDM,	  IDDM,	  and	  those	  
without	  DM	  using	  Poisson	  regression	  with	  robust	  error	  variance.	  	  These	  multivariate	  
analyses	  were	  adjusted	  for	  the	  demographics	  of	  age	  (15–54,	  55–64,	  65–74,	  ≥75	  years	  
old),	  sex,	  BMI	  (18–24,	  25–29,	  30–34,	  and	  ≥	  35	  kg/m2),	  CCI,	  and	  smoking	  status	  in	  order	  
to	  control	  for	  potential	  confounders.	  	  Poisson	  regression	  with	  robust	  error	  variance	  was	  
used	  as	  an	  alternative	  to	  logistic	  regression	  so	  that	  the	  strengths	  of	  association	  could	  be	  
reported	  as	  relative	  risks	  rather	  than	  odds	  ratios.76,77	  







In	  total,	  71,733	  patients	  who	  underwent	  THA	  between	  the	  years	  of	  2005	  and	  2014	  were	  
identified	  in	  the	  ACS	  NSQIP	  database,	  and	  6,305	  of	  these	  patients	  (9%)	  had	  NIDDM,	  
1,920	  patients	  (3%)	  had	  IDDM,	  and	  63,508	  patients	  did	  not	  have	  DM	  (88%).	  	  
	  
Table	  1	  presents	   the	  differences	   in	  demographics	  of	  patients	  with	  NIDDM,	   IDDM,	  and	  
patients	   without	   DM.	   	   Patients	   with	   DM	   were	   older	   than	   patients	   without	   DM	   (p	   <	  
0.001).	  	  Patients	  with	  DM	  were	  more	  likely	  to	  be	  male	  (p	  <	  0.001).	  	  Patients	  with	  IDDM	  
were	  more	  likely	  to	  have	  a	  BMI	  greater	  than	  35	  kg/m2.	  	  Patients	  with	  NIDDM	  and	  IDDM	  
had	   greater	   CCIs	   than	   those	   without	   DM	   (p	   <	   0.001).	   	   Patients	   who	   were	   current	  
smokers	   were	   not	   equally	   distributed	   between	   groups	   (p	   =	   0.016),	   but	   the	   real	  
differences	  in	  smoking	  rates	  were	  small	  (See	  Table	  1).	  
	  
Patients	  with	  NIDDM	  had	  an	  increased	  relative	  risk	  for	  3	  of	  17	  adverse	  events	  relative	  to	  
patients	  without	  DM.	  	  These	  were	  sepsis	  or	  septic	  shock	  (relative	  risk	  [RR]	  =	  1.90,	  99.7%	  
confidence	  interval	  [CI]	  =	  1.14	  -­‐	  3.19,	  p	  <	  0.001),	  readmission	  (RR	  =	  1.28,	  CI	  =	  1.06	  -­‐	  1.55,	  
p	  <	  0.001),	  and	  extended	  LOS	  (RR	  =	  1.35,	  CI	  =	  1.16	  -­‐	  1.58,	  p	  <	  0.001).	  	  These	  results	  are	  
shown	  in	  Table	  2	  and	  they	  are	  represented	  graphically	  in	  a	  forest	  plot	  in	  Figure	  1.	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Patients	  with	  IDDM	  were	  at	  increased	  relative	  risk	  for	  11	  of	  17	  adverse	  events	  relative	  to	  
patients	  without	  DM.	  	  These	  were	  death	  (RR	  =	  5.92,	  CI	  =	  2.07	  -­‐	  16.93,	  p	  <	  0.001),	  sepsis	  
or	  septic	  shock	  (RR	  =	  3.53,	  CI	  =	  1.86	  -­‐	  6.70,	  p	  <	  0.001),	  myocardial	  infarction	  (RR	  =	  4.65,	  
CI	  =	  2.31	  -­‐	  9.34,	  p	  <	  0.001),	  wound-­‐related	  infection	  (RR	  =	  1.95,	  CI	  =	  1.29	  -­‐	  2.96,	  p	  <	  
0.001),	  unplanned	  intubation	  (RR	  =	  3.03,	  CI	  =	  1.29	  -­‐	  7.11,	  p	  <	  0.001),	  renal	  insufficiency	  
(RR	  =	  6.26,	  CI	  =	  2.23	  -­‐	  17.52,	  p	  <	  0.001),	  return	  to	  the	  operating	  room	  (RR	  =	  1.53,	  CI	  =	  
1.05	  -­‐	  2.22,	  p	  <	  0.001),	  readmission	  (RR	  =	  2.11,	  CI	  =	  1.64	  -­‐	  2.73,	  p	  <	  0.001),	  pneumonia	  
(RR	  =	  4.17,	  CI	  =	  2.18	  -­‐	  7.98,	  p	  <	  0.001),	  urinary	  tract	  infection	  (RR	  =	  1.73,	  CI	  =	  1.06	  -­‐	  2.81,	  
p	  <	  0.001),	  and	  extended	  length	  of	  stay	  (RR	  =	  2.26,	  CI	  =	  1.85	  -­‐	  2.76,	  p	  <	  0.001).	  	  These	  
results	  are	  shown	  in	  Table	  2	  and	  they	  are	  represented	  graphically	  in	  a	  forest	  plot	  in	  
Figure	  2.	  	  	  
	  
Many	  more	  adverse	  events	  were	  associated	  with	  IDDM	  than	  with	  NIDDM.	  	  Furthermore,	  
the	  relative	  risks	  of	  adverse	  events	  were	  greater	  for	  patients	  with	  IDDM	  than	  for	  
patients	  with	  NIDDM	  (sepsis	  or	  septic	  shock:	  RR	  =	  3.53	  versus	  1.90,	  respectively,	  
readmission:	  RR	  =	  2.11	  vs.	  1.28,	  and	  LOS:	  RR	  =	  2.26	  vs.	  1.35).	  







Multiple	  studies	  have	  shown	  that	  DM	  is	  associated	  with	  an	  increased	  rate	  of	  adverse	  
events	  after	  THA.34-­‐44,55,57	  	  Many	  of	  the	  prior	  studies,	  however,	  did	  not	  distinguish	  
between	  identifiable	  subpopulations	  of	  patients	  with	  DM.	  	  Many	  factors	  could	  be	  used	  
to	  identify	  subpopulations	  that	  are	  at	  increased	  risk	  for	  adverse	  events	  after	  THA,	  and	  
this	  information	  could	  be	  useful	  for	  patients	  and	  providers.	  
	  
This	  study	  of	  a	  large	  cohort	  of	  patients	  with	  DM	  who	  underwent	  THA	  found	  that	  
patients	  who	  use	  insulin	  in	  the	  management	  of	  diabetes	  are	  at	  great	  risk	  for	  
perioperative	  adverse	  events	  independent	  of	  demographic	  and	  comorbid	  factors.	  	  The	  
results	  of	  this	  study	  are	  consistent	  with	  recent	  research	  that	  shows	  that	  patients	  with	  
IDDM	  are	  at	  a	  greater	  risk	  for	  medical	  complications	  when	  undergoing	  TJA,	  57	  but	  this	  
study	  shows	  that	  insulin	  dependence	  is	  also	  an	  independent	  risk	  factor	  for	  many	  specific	  
adverse	  events	  including	  death,	  sepsis	  or	  septic	  shock,	  myocardial	  infarction,	  wound-­‐
related	  infection,	  unplanned	  intubation,	  renal	  insufficiency,	  return	  to	  the	  operating	  
room,	  readmission,	  pneumonia,	  urinary	  tract	  infection,	  and	  extended	  length	  of	  stay	  




There	  are	  limitations	  to	  this	  analysis.	  	  The	  reliability	  of	  findings	  that	  are	  based	  on	  
database	  studies	  is	  controversial.	  	  Specific	  to	  THA,	  a	  recent	  study	  found	  differences	  
between	  populations	  and	  outcomes	  between	  the	  National	  Hospital	  Discharge	  Survey	  
(NHDS)	  database	  and	  the	  Nationwide	  Inpatient	  Sample	  (NIS)	  database	  and	  that	  study	  
concluded	  that	  large	  databases	  can	  have	  limited	  reliability	  and	  should	  be	  interpreted	  
with	  caution.78	  	  While	  that	  study	  used	  the	  administratively-­‐coded	  NHDS	  and	  NIS,	  this	  
study	  used	  the	  professionally	  chart-­‐abstracted	  ACS	  NSQIP	  database	  which	  differs	  
significantly	  from	  NHDS	  and	  NIS	  in	  methods	  of	  data	  collection	  and	  follow-­‐up.	  	  In	  contrast	  
to	  the	  data	  in	  administrative	  databases	  that	  are	  based	  on	  reimbursement	  claims	  and	  
have	  been	  shown	  to	  be	  limited,62	  inconsistent,63	  and	  fraught	  with	  errors,64	  ACS	  NSQIP	  
data	  are	  chart-­‐abstracted	  and	  prospectively	  collected,	  and	  high-­‐quality	  data	  is	  ensured	  
by	  routine	  auditing.	  	  This	  is	  demonstrated	  by	  an	  agreement	  rate	  between	  clinical	  
reviewers	  of	  greater	  than	  98%.65	  	  Reliability	  and	  internal	  validity	  are	  particularly	  
important	  when	  cohorts	  are	  defined	  by	  clinical	  criteria	  and	  for	  these	  reasons	  cohorts	  
identified	  in	  the	  ACS	  NSQIP	  database	  may	  be	  considered	  to	  more	  accurately	  reflect	  the	  
real	  characteristics	  of	  the	  study	  population	  and	  the	  rates	  of	  adverse	  events	  than	  studies	  
that	  use	  the	  administratively-­‐coded	  NHDS	  and	  NIS	  databases.	  
	  
However,	  in	  this	  study	  patients	  with	  IDDM,	  NIDDM,	  and	  without	  DM	  are	  defined	  by	  
their	  use	  of	  insulin	  or	  other	  medications.	  	  For	  this	  reason,	  it	  is	  possible	  that	  some	  
patients	  who	  actually	  have	  DM	  are	  included	  in	  the	  group	  without	  DM	  if	  those	  patients	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are	  not	  using	  any	  medications	  to	  control	  hyperglycemia.	  	  Furthermore,	  the	  ACS	  NSQIP	  
database	  does	  not	  record	  perioperative	  glucose	  levels	  or	  indicators	  of	  glycemic	  control.	  	  
Recent	  studies	  have	  shown	  that	  lowering	  average	  blood	  glucose	  in	  the	  three	  months	  
prior	  to	  surgery	  may	  be	  important	  to	  prevent	  postoperative	  morbidity	  and	  mortality61	  
and	  that	  the	  relationship	  between	  average	  blood	  glucose	  level	  and	  complication	  risk	  is	  
linear.79	  	  Average	  blood	  glucose	  is	  often	  monitored	  by	  glycated	  hemoglobin	  (HbA1c)	  
level,	  but	  because	  the	  ACS	  NSQIP	  database	  does	  not	  record	  HbA1c	  levels	  the	  average	  
blood	  glucose	  level	  of	  patients	  before	  surgery	  or	  in	  the	  postoperative	  period	  could	  not	  
be	  evaluated,	  and	  this	  is	  a	  limitation	  of	  this	  study.	  	  Because	  the	  multivariate	  analyses	  
could	  not	  be	  adjusted	  for	  HbA1c	  level,	  it	  is	  not	  possible	  to	  determine	  whether	  or	  not	  
insulin	  dependence	  is	  a	  risk	  factor	  independent	  of	  average	  blood	  glucose	  level.	  	  Studies	  
have	  also	  shown	  that	  perioperative	  glycemic	  control	  is	  an	  important	  risk	  factor	  for	  
adverse	  events,80	  but	  perioperative	  blood	  glucose	  levels	  are	  not	  recorded	  in	  the	  ACS	  
NSQIP	  database	  either,	  and	  for	  this	  reason	  this	  study	  is	  unable	  to	  determine	  if	  insulin	  
dependence	  is	  a	  risk	  factor	  independent	  of	  perioperative	  blood	  glucose	  levels.	  
	  
It	  should	  be	  mentioned	  that	  the	  mechanism	  of	  the	  association	  between	  IDDM	  and	  the	  
risk	  of	  adverse	  events	  is	  not	  known.	  	  For	  example,	  the	  results	  of	  this	  study	  should	  not	  be	  
interpreted	  to	  imply	  that	  insulin	  use	  itself	  is	  directly	  associated	  with	  adverse	  events,	  and	  
perioperative	  insulin	  regimens	  should	  not	  be	  modified	  based	  on	  the	  results	  of	  this	  study.	  	  
It	  is	  possible	  that	  patients	  with	  IDDM	  more	  often	  have	  advanced	  DM	  relative	  to	  patients	  
with	  NIDDM,	  and	  this	  may	  account	  for	  some	  of	  the	  differences	  in	  the	  relative	  risks	  of	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adverse	  events,	  but	  advanced	  DM	  may	  not	  account	  for	  all	  of	  the	  differences,	  and	  this	  
should	  be	  an	  area	  of	  future	  research.	  
	  
Despite	  these	  limitations,	  this	  study	  of	  postoperative	  adverse	  events	  in	  71,733	  patients	  
with	  DM	  who	  underwent	  THA	  in	  a	  prospectively-­‐collected	  national	  database	  has	  shown	  
for	  the	  first	  time	  that	  IDDM	  is	  an	  independent	  risk	  factor	  for	  11	  distinct	  perioperative	  
adverse	  events	  while	  patients	  with	  NIDDM	  are	  at	  increased	  risk	  for	  only	  3	  of	  these	  
adverse	  events	  relative	  to	  patients	  without	  DM.	  	  Absolute	  risks	  of	  these	  adverse	  events	  
given	  patient	  demographics	  and	  comorbidities	  can	  be	  found	  using	  the	  ACS	  NSQIP	  
surgical	  risk	  calculator	  at	  (http://riskcalculator.facs.org).59	  	  This	  study	  controlled	  for	  
those	  demographics	  and	  comorbidities	  to	  show	  that	  patients	  with	  IDDM	  had	  increased	  
relative	  risk	  of	  many	  more	  adverse	  events	  than	  patients	  with	  NIDDM	  relative	  to	  patients	  
without	  DM	  independent	  of	  demographics	  and	  comorbidities.	  







The	  results	  of	  this	  study	  show	  that	  insulin	  dependence	  is	  an	  independent	  risk	  factor	  for	  
adverse	  events	  after	  THA.	  	  Orthopaedic	  surgeons	  should	  be	  aware	  of	  the	  utility	  of	  insulin	  
dependence	  as	  a	  predictor	  of	  adverse	  events.	  	  Although	  the	  relationship	  between	  
average	  blood	  glucose	  level	  as	  measured	  by	  HbA1c	  and	  perioperative	  glycemic	  control	  
as	  measured	  by	  perioperative	  blood	  glucose	  level	  are	  well	  recognized	  risk	  factors	  for	  
adverse	  events,60	  the	  association	  between	  insulin	  dependence	  and	  the	  risks	  for	  adverse	  
events	  has	  not	  been	  well	  appreciated.	  	  This	  information	  will	  be	  useful	  for	  patient	  
selection,	  preoperative	  risk	  stratification,	  and	  postoperative	  expectations.	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COMPARISON	  OF	  PERIOPERATIVE	  ADVERSE	  EVENT	  RATES	  FOLLOWING	  TOTAL	  KNEE	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Background	  –	  Total	  knee	  arthroplasty	  (TKA)	  is	  an	  effective	  treatment	  option	  for	  patients	  
with	  advanced	  osteoarthritis	  and	  has	  become	  one	  of	  the	  most	  frequently	  performed	  
orthopaedic	  procedures.	  	  With	  the	  increasing	  prevalence	  of	  diabetes	  mellitus	  (DM)	  the	  
burden	  of	  its	  sequelae	  and	  associated	  surgical	  complications	  has	  also	  increased,	  and	  1	  in	  
5	  patients	  in	  the	  US	  who	  will	  undergo	  total	  joint	  arthroplasty	  has	  DM.	  	  For	  these	  
reasons,	  it	  is	  important	  to	  understand	  the	  association	  between	  DM	  and	  the	  rates	  of	  
perioperative	  adverse	  events	  following	  TKA.	  
	  
Methods	  –	  A	  retrospective	  cohort	  study	  was	  conducted	  using	  the	  American	  College	  of	  
Surgeons	  National	  Surgical	  Quality	  Improvement	  Program	  (ACS	  NSQIP)	  database.	  
Patients	  who	  underwent	  TKA	  between	  the	  years	  2005	  and	  2014	  were	  identified	  and	  
characterized	  as	  having	  insulin	  dependent	  diabetes	  mellitus	  (IDDM),	  non-­‐insulin	  
dependent	  diabetes	  mellitus	  (NIDDM),	  or	  neither.	  	  Multivariate	  Poisson	  regression	  was	  
used	  to	  control	  for	  demographic	  and	  comorbid	  factors	  and	  to	  assess	  the	  relative	  risks	  of	  
multiple	  adverse	  events	  in	  the	  initial	  30	  postoperative	  days.	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Result	  –	  A	  total	  of	  114,102	  patients	  who	  underwent	  TKA	  were	  selected	  (4,881	  (4.3%)	  
with	  IDDM,	  15,367	  (13.5%)	  with	  NIDDM,	  and	  93,854	  (82.2%)	  without	  DM).	  	  Compared	  to	  
patients	  with	  out	  DM,	  patients	  with	  NIDDM	  were	  found	  to	  be	  at	  an	  increased	  relative	  
risk	  for	  2	  of	  17	  adverse	  events	  studied.	  	  These	  were	  myocardial	  infarction	  (MI)	  and	  
extended	  postoperative	  length	  of	  stay	  (LOS)	  (greater	  than	  5	  days).	  	  Compared	  to	  
patients	  with	  out	  DM,	  patients	  with	  IDDM	  were	  found	  to	  be	  at	  an	  increased	  relative	  risk	  
for	  12	  of	  17	  adverse	  events	  studied.	  	  These	  were	  sepsis	  or	  septic	  shock,	  MI,	  renal	  failure,	  
ventilator	  time	  great	  than	  48	  hours,	  unplanned	  intubation,	  renal	  insufficiency,	  return	  to	  
the	  operating	  room,	  wound	  dehiscence,	  readmission	  to	  hospital	  within	  30	  postoperative	  
days,	  pneumonia,	  urinary	  tract	  infection,	  and	  extended	  LOS.	  	  Patients	  with	  IDDM	  and	  
NIDDM	  were	  both	  at	  greater	  risk	  for	  MI	  and	  extended	  LOS.	  	  Patients	  with	  IDDM	  were	  at	  
greater	  risk	  for	  MI	  (relative	  risk	  [RR]	  =	  2.71	  versus	  1.67)	  and	  extended	  LOS	  (RR	  =	  1.99	  
versus	  1.42).	  
	  
Conclusions	  –	  Compared	  to	  patients	  with	  NIDDM,	  patients	  with	  IDDM	  are	  at	  greater	  risk	  
for	  many	  more	  perioperative	  adverse	  relative	  to	  patients	  without	  DM.	  	  These	  findings	  
have	  important	  implications	  for	  patient	  selection,	  preoperative	  risk	  stratification,	  and	  
postoperative	  expectations.	  







Total	  knee	  arthroplasty	  (TKA)	  is	  one	  of	  the	  most	  commonly	  performed	  orthopaedic	  
procedures	  in	  the	  United	  States	  (US)	  and	  the	  number	  of	  TKAs	  performed	  in	  the	  US	  per	  
annum	  continues	  to	  increase.2,46,56,69	  	  Concurrently,	  the	  prevalence	  of	  diabetes	  mellitus	  
(DM)	  in	  the	  US	  is	  also	  increasing,9-­‐11	  and	  the	  effects	  of	  DM	  on	  surgical	  outcomes	  has	  
become	  a	  greater	  focus	  as	  surgeons	  explore	  all	  avenues	  to	  optimize	  patient	  outcomes.	  	  
In	  2009,	  20%	  of	  the	  patients	  in	  the	  Nationwide	  Inpatient	  Sample	  had	  DM7	  and	  19%	  of	  
patients	  in	  the	  Kaiser	  Permanente	  Total	  Joint	  Replacement	  Registry	  had	  DM.6	  
	  
Patients	  with	  DM	  have	  been	  found	  to	  have	  a	  greater	  risk	  of	  complications	  than	  patients	  
without	  DM	  following	  many	  orthopaedic	  procedures.55,61,66,67	  	  In	  particular,	  previous	  
retrospective	  studies	  have	  found	  that	  relative	  to	  patients	  without	  DM	  those	  patients	  
with	  DM	  who	  underwent	  TKA	  had	  greater	  rates	  of	  mortality,47	  surgical	  site	  
infections,41,48,49,56,57,81	  and	  periprosthetic	  joint	  infections.39,40	  	  Patients	  with	  DM	  were	  
also	  more	  likely	  to	  be	  discharged	  to	  a	  location	  other	  than	  home50	  and	  to	  be	  readmitted	  
to	  hospital.42	  	  Patients	  with	  DM	  were	  also	  more	  likely	  to	  experience	  periprosthetic	  
fracture	  and	  aseptic	  loosening,4	  persistent	  pain	  in	  the	  operated	  joint,35	  and	  revision	  
arthroplasty	  within	  5	  years.52	  	  Additionally,	  patients	  with	  DM	  also	  had	  poorer	  functional	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outcomes51	  and	  higher	  resource	  utilization	  following	  total	  joint	  arthroplasty.61	  	  These	  
studies,	  however,	  have	  generally	  categorized	  patients	  as	  either	  those	  with	  DM	  or	  those	  
without	  DM	  and	  in	  doing	  so	  prior	  studies	  have	  not	  recognized	  important	  differences	  
among	  patients	  with	  DM	  that	  may	  be	  useful	  as	  predictors	  of	  adverse	  events.	  	  	  
	  
Due	  to	  the	  large	  number	  of	  patients	  therein,	  national	  databases	  and	  registries	  enable	  
the	  analysis	  of	  rare	  adverse	  events	  and	  particular	  subpopulations.	  	  The	  American	  College	  
of	  Surgeons	  National	  Surgical	  Quality	  Improvement	  Program	  (ACS	  NSQIP)	  is	  one	  such	  
database	  that	  has	  received	  specific	  attention	  due	  to	  high-­‐quality,	  chart-­‐abstracted	  data	  
that	  is	  collected	  for	  30	  days	  postoperatively	  regardless	  of	  hospital	  discharge.31,69	  	  To	  that	  
end,	  a	  recent	  ACS	  NSQIP	  study	  evaluating	  the	  effect	  of	  diabetes	  on	  outcomes	  after	  
lumbar	  fusion	  found	  that	  those	  with	  insulin	  dependent	  diabetes	  mellitus	  (IDDM)	  were	  at	  
greater	  risk	  for	  many	  more	  perioperative	  adverse	  events	  than	  patients	  with	  non-­‐insulin	  
dependent	  diabetes	  mellitus	  (NIDDM).66	  
	  
There	  is	  also	  a	  single	  institution	  study	  from	  the	  Mayo	  Clinic	  in	  Rochester,	  MN	  in	  which	  all	  
morbidly	  obese	  patients	  (BMI	  >	  40	  kg/m2)	  who	  underwent	  primary	  TKA	  between	  1995	  
and	  2011	  with	  a	  minimum	  of	  two	  years	  of	  follow-­‐up	  were	  retrospectively	  reviewed.	  	  
This	  study	  found	  that	  patients	  with	  DM	  type	  2	  had	  similar	  outcomes	  as	  patients	  without	  
DM,	  but	  patients	  with	  DM	  type	  2	  and	  insulin	  dependence	  had	  increased	  risks	  of	  
reoperation,	  revision,	  periprosthetic	  joint	  infection,	  and	  decreased	  10-­‐year	  implant	  
survivorship	  when	  compared	  to	  patients	  without	  DM.53	  	  However,	  other	  than	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periprosthetic	  joint	  infection	  that	  study	  did	  not	  investigate	  the	  rates	  of	  any	  of	  the	  other	  
adverse	  events	  that	  this	  study	  investigates.	  
	  
A	  study	  of	  the	  ACS	  NSQIP	  database	  from	  2006	  to	  2010	  found	  that	  patient	  age	  and	  
diabetes	  were	  both	  independent	  predictors	  of	  30	  day	  mortality	  after	  TKA.47	  	  That	  study	  
included	  15,321	  patients	  and	  did	  not	  stratify	  patients	  by	  insulin	  dependence.	  	  This	  study	  
of	  ACS	  NSQIP	  from	  2005-­‐2014	  includes	  114,102	  patients	  and	  does	  stratify	  by	  insulin	  
dependence.	  
	  
One	  prior	  study	  of	  the	  ACS	  NSQIP	  database	  has	  evaluated	  the	  effect	  of	  IDDM	  and	  
NIDDM	  in	  the	  total	  joint	  population	  based	  on	  data	  through	  2011.	  	  Overall,	  a	  greater	  risk	  
of	  postoperative	  infection	  was	  identified	  in	  the	  IDDM	  cohort	  (7%	  versus	  5%).	  	  Patients	  
with	  IDDM	  were	  also	  at	  greater	  risk	  for	  a	  “medical	  complication”57	  which	  is	  a	  composite	  
of	  many	  complications.	  	  However,	  that	  analysis	  considered	  total	  hip	  arthroplasty	  
patients	  together	  with	  TKA	  patients,	  and	  did	  not	  find	  that	  IDDM	  patients	  were	  at	  greater	  
risk	  for	  any	  particular	  complications	  other	  than	  infection	  relative	  to	  patients	  without	  
DM.	  	  In	  addition,	  since	  the	  time	  of	  that	  study	  the	  number	  of	  TKA	  cases	  available	  in	  the	  
ACS	  NSQIP	  database	  has	  more	  than	  quadrupled,	  allowing	  our	  study	  to	  be	  powered	  to	  
investigate	  associations	  that	  were	  not	  initially	  apparent.	  	  This	  study	  identifies	  particular	  
medical	  complications	  for	  which	  patients	  with	  IDDM	  are	  at	  risk.	  
	  
 41	  
A	  goal	  of	  the	  current	  study	  is	  to	  assess	  the	  relative	  risk	  of	  adverse	  events	  after	  TKA	  in	  
patients	  with	  IDDM	  and	  NIDDM	  in	  comparison	  to	  patients	  without	  DM.	  	  This	  
information	  will	  be	  useful	  for	  patient	  counseling	  and	  risk	  stratification,	  preoperative	  
planning,	  and	  postoperative	  surveillance.	  	  Adequate	  assessment	  of	  risks	  will	  facilitate	  
appropriate	  patient	  education	  and	  surgeon	  preparedness	  in	  regard	  to	  the	  risks	  of	  
adverse	  events.	  
	  





MATERIALS	  &	  METHODS	  
	  
The	  ACS	  NSQIP	  database	  gathers	  patient	  data	  from	  517	  participating	  hospitals	  in	  the	  US.	  	  
Data	  is	  collected	  during	  the	  entire	  30	  day	  postoperative	  period	  regardless	  of	  hospital	  
discharge,	  and	  data	  is	  de-­‐identified	  before	  being	  shared	  with	  participating	  institutions.	  	  
The	  current	  study	  was	  approved	  by	  the	  Human	  Investigation	  Committee	  at	  our	  
institution.	  
	  
Patients	  who	  underwent	  TKA	  were	  identified	  using	  Current	  Procedural	  Terminology	  
code	  27447.	  	  Demographic	  variables	  available	  from	  the	  ACS	  NSQIP	  database	  include	  
patient	  age,	  sex,	  height,	  weight,	  and	  smoking	  status	  (current	  smoker	  within	  1	  year).	  	  
Body	  mass	  index	  (BMI)	  was	  calculated	  using	  patient	  height	  and	  weight.	  
	  
For	  each	  case,	  a	  comorbidity	  score	  was	  calculated	  using	  a	  modified	  version	  of	  the	  
Charlson	  comorbidity	  index	  (CCI)70	  that	  has	  been	  adapted	  to	  the	  ACS	  NSQIP	  database.71	  	  
Studies	  have	  demonstrated	  that	  such	  modified	  CCIs	  predict	  similar	  outcomes	  as	  the	  
original	  CCI.72,73	  	  The	  comorbidities	  used	  to	  determine	  the	  modified	  CCI	  include	  
(followed	  by	  their	  CCI	  point	  values):	  myocardial	  infarction	  within	  the	  six	  months	  prior	  to	  
surgery	  (1),	  congestive	  heart	  failure	  (1),	  peripheral	  vascular	  disease	  or	  rest	  pain	  (1),	  any	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history	  of	  transient	  ischemic	  attack	  or	  cerebrovascular	  accident	  (1),	  chronic	  obstructive	  
pulmonary	  disease	  (1),	  diabetes	  mellitus	  (1),	  hemiplegia	  (2),	  end	  stage	  renal	  disease	  (2),	  
ascites	  or	  esophageal	  varices	  (3),	  and	  disseminated	  cancer	  (6).	  	  To	  calculate	  the	  CCI	  for	  a	  
given	  case	  these	  point	  values	  are	  summed	  and	  an	  additional	  point	  is	  added	  for	  each	  age	  
decade	  older	  than	  age	  40.	  	  Although	  DM	  is	  included	  as	  a	  comorbid	  condition	  in	  the	  
original	  CCI,	  it	  was	  removed	  from	  the	  modified	  CCI	  calculation	  for	  this	  study	  because	  DM	  
is	  the	  comorbidity	  that	  this	  study	  investigates.	  
	  
The	  ACS	  NSQIP	  database	  tracks	  patients	  for	  the	  occurrence	  of	  individual	  adverse	  events	  
during	  the	  first	  30	  postoperative	  days.	  	  A	  prior	  study	  in	  our	  group	  asked	  orthopaedic	  
surgeons	  at	  multiple	  institutions	  to	  weight	  each	  of	  these	  complications	  relative	  to	  a	  
single	  patient’s	  death.	  	  In	  order	  of	  severity	  weight	  relative	  to	  death74	  these	  adverse	  
events	  are	  (weight):	  death	  (1),	  cardiac	  arrest	  requiring	  cardiopulmonary	  resuscitation	  
(0.151),	  stroke	  or	  cerebrovascular	  accident	  (0.010),	  septic	  shock	  (0.087),	  myocardial	  
infarction	  (0.042),	  acute	  renal	  failure	  (0.040),	  pulmonary	  embolism	  (0.030),	  sepsis	  
(0.018),	  organ	  space	  infection	  (0.018),	  ventilator	  time	  greater	  than	  48	  hours	  (0.015),	  
deep	  surgical	  site	  infection	  (0.015),	  unplanned	  intubation	  (0.014),	  renal	  insufficiency	  
(0.009),	  return	  to	  the	  operating	  room	  (0.009),	  superficial	  surgical	  site	  infection	  (0.007),	  
deep	  vein	  thrombosis	  (0.006),	  wound	  dehiscence	  (0.006),	  readmission	  to	  hospital	  
(0.006),	  pneumonia	  (0.006),	  and	  urinary	  tract	  infection	  (0.003).	  	  In	  this	  study,	  pulmonary	  
embolism	  and	  deep	  vein	  thrombosis	  were	  considered	  together	  as	  “thrombotic	  events,”	  
superficial	  surgical	  site	  infection,	  deep	  wound	  infection,	  and	  organ	  space	  infection	  were	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considered	  together	  as	  a	  “wound-­‐related	  infections,”	  and	  sepsis	  and	  septic	  shock	  were	  
also	  considered	  together.	  
	  
Postoperative	  length	  of	  stay	  (LOS)	  and	  readmission	  are	  also	  directly	  reported	  in	  the	  ACS	  
NSQIP	  database.	  	  LOS	  is	  defined	  as	  the	  number	  of	  days	  from	  the	  operation	  date	  until	  
discharge.	  	  Readmission	  is	  defined	  as	  any	  admission	  for	  any	  reason	  that	  occurs	  after	  
discharge	  and	  within	  30	  days	  of	  surgery.	  	  While	  most	  postoperative	  variables	  in	  the	  ACS	  
NSQIP	  database	  are	  only	  reported	  if	  they	  occur	  within	  the	  first	  30	  days,	  postoperative	  
LOS	  is	  reported	  beyond	  30	  days.	  	  However,	  in	  order	  to	  limit	  the	  influence	  of	  outliers	  on	  
the	  analysis	  this	  study	  considered	  patients	  with	  postoperative	  LOS	  longer	  than	  30	  days	  
to	  have	  had	  postoperative	  LOS	  equal	  to	  30	  days.	  	  Length	  of	  stay	  was	  considered	  to	  be	  
extended	  if	  the	  stay	  lasted	  longer	  than	  one	  standard	  deviation	  (1.8	  days)	  longer	  than	  the	  
mean	  (3.2	  days)	  of	  all	  hospital	  stays	  in	  the	  cohort.	  	  For	  this	  reason,	  any	  LOS	  longer	  than	  
5	  days	  was	  considered	  to	  be	  extended.	  
	  
The	  occurrence	  of	  readmission	  within	  30	  days	  of	  surgery	  is	  reported	  in	  the	  ACS	  NSQIP	  
database	  for	  cases	  that	  occurred	  in	  2011	  or	  later,	  but	  not	  for	  earlier	  cases.	  	  Hence,	  the	  
analysis	  of	  readmission	  includes	  only	  99,508	  of	  114,102	  cases,	  but	  this	  represents	  87.2%	  
of	  all	  cases	  included	  in	  this	  study.	  
	  
The	  ACS	  NSQIP	  database	  records	  one	  of	  three	  possible	  DM	  statuses	  for	  each	  case.	  	  
Patients	  are	  either	  those	  who	  use	  daily	  insulin	  therapy	  to	  treat	  their	  diabetes	  (IDDM),	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those	  who	  use	  non-­‐insulin	  pharmacologic	  agents	  (NIDDM),	  or	  patients	  who	  do	  not	  have	  
DM.	  	  Patients	  who	  do	  not	  have	  DM	  either	  do	  not	  have	  insulin	  resistance	  or	  
hyperglycemia	  or	  are	  using	  dietary	  modifications	  alone	  to	  control	  hyperglycemia.	  
	  
Statistical	  analyses	  were	  performed	  using	  STATA	  version	  13	  (StataCorp	  LP,	  College	  
Station,	  TX).	  	  Statistical	  significance	  was	  set	  at	  a	  2-­‐sided	  alpha	  level	  of	  0.05,	  but	  because	  
the	  chance	  of	  finding	  one	  or	  more	  spurious	  significant	  differences	  in	  17	  tests	  is	  58.2%	  
the	  level	  of	  significance	  for	  comparisons	  of	  adverse	  event	  rate	  for	  each	  of	  these	  17	  
adverse	  events	  was	  adjusted	  to	  0.003	  according	  to	  Bonferroni’s	  correction.75	  	  Likewise,	  
instead	  of	  reporting	  95%	  confidence	  intervals	  of	  these	  relative	  risks,	  99.7%	  confidence	  
intervals	  are	  reported	  in	  this	  study.	  	  Demographics	  were	  compared	  between	  patients	  
with	  NIDDM,	  patients	  with	  IDDM,	  and	  those	  without	  DM	  using	  Pearson	  chi-­‐squared	  
tests.	  	  	  
	  
Adverse	  event	  rates	  were	  compared	  between	  patients	  with	  NIDDM,	  IDDM,	  and	  those	  
without	  DM	  using	  Poisson	  regression	  with	  robust	  error	  variance.	  	  These	  multivariate	  
analyses	  were	  adjusted	  for	  the	  demographics	  of	  age	  (15–54,	  55–64,	  65–74,	  ≥75	  years	  
old),	  sex,	  BMI	  (18–24,	  25–29,	  30–34,	  and	  ≥	  35	  kg/m2),	  CCI,	  and	  smoking	  status	  in	  order	  
to	  control	  for	  potential	  confounders.	  	  Poisson	  regression	  with	  robust	  error	  variance	  was	  
used	  as	  an	  alternative	  to	  logistic	  regression	  so	  that	  the	  strengths	  of	  association	  could	  be	  
reported	  as	  relative	  risks	  rather	  than	  odds	  ratios.76,77
Ellman, Matthew  4/27/2016 12:36 AM
Comment [1]: 	  Might	  say	  patients	  who	  are	  classified	  as	  not	  having	  DM	  include	  patients	  without	  DM	  or	  those	  with	  DM	  who	  are	  not	  using	  medication	  for	  DM.	  We	  don’t	  really	  know	  whether	  diet	  /lifestyle	  is	  being	  used	  to	  control	  hyperglycemia,	  just	  that	  they	  are	  not	  on	  medication.	  	  	  	  Also:	  was	  analysis	  done	  based	  on	  DM	  or	  no	  DM	  (I	  see	  this	  was	  removed	  from	  CCI)	  or	  determined	  among	  those	  on	  no	  DM	  medicines	  what	  percentage	  have	  DM	  listed	  in	  their	  history?	  If	  so,	  that	  would	  be	  useful	  to	  report.	  
Matthew Webb   4/27/2016 12:36 AM







In	  total,	  114,102	  patients	  who	  underwent	  TKA	  between	  the	  years	  of	  2005	  and	  2014	  
were	  identified	  in	  the	  ACS	  NSQIP	  database.	  	  Of	  these,	  15,367	  patients	  (14%)	  had	  NIDDM,	  
4,881	  patients	  (4%)	  had	  IDDM,	  and	  93,854	  patients	  did	  not	  have	  DM	  (82%).	  	  
	  
Table	  1	  presents	  the	  differences	  in	  demographics	  of	  patients	  with	  NIDDM,	  patients	  with	  
IDDM,	  and	  patients	  without	  DM.	   	   Patients	  with	  DM	  were	  older	   than	  patients	  without	  
DM	   (p	  <	  0.001).	   	  Patients	  with	  DM	  were	  more	   likely	   to	  be	  male	   (p	  <	  0.001).	   	  Patients	  
with	  IDDM	  were	  more	  likely	  to	  have	  a	  BMI	  greater	  than	  35	  kg/m2.	  	  Patients	  with	  NIDDM	  
of	  IDDM	  had	  a	  greater	  CCI	  than	  those	  without	  DM	  (p	  <	  0.001).	  	  There	  was	  no	  difference	  
in	  smoking	  status	  between	  patients	  with	  NIDDM,	  patients	  with	  IDDM,	  and	  those	  without	  
DM	  (p	  =	  0.050).	  
	  
Compared	  to	  patients	  without	  DM,	  patients	  with	  NIDDM	  had	  an	  increased	  relative	  risk	  
for	  2	  of	  17	  adverse	  events	  studied.	  	  These	  were	  myocardial	  infarction	  (MI)	  (relative	  risk	  
[RR]	  =	  1.67,	  99.7%	  confidence	  interval	  [CI]	  =	  1.01	  -­‐	  2.77,	  p	  =	  0.002)	  and	  extended	  LOS	  
(RR	  =	  1.42,	  CI	  =	  1.28	  -­‐	  1.57,	  p	  <	  0.001).	  	  These	  results	  are	  shown	  in	  Table	  2	  and	  they	  are	  
represented	  graphically	  in	  a	  forest	  plot	  in	  Figure	  1.	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Compared	  to	  patients	  without	  DM,	  patients	  with	  IDDM	  were	  at	  increased	  relative	  risk	  
for	  12	  of	  17	  adverse	  events	  investigated.	  	  These	  were	  sepsis	  or	  septic	  shock	  (RR	  =	  2.42,	  
CI	  =	  1.38	  -­‐	  4.23,	  p	  <	  0.001),	  MI	  (RR	  =	  2.71,	  CI	  =	  1.38	  -­‐	  5.33,	  p	  <	  0.001),	  renal	  failure	  (RR	  =	  
4.66,	  CI	  =	  1.78	  -­‐	  12.22,	  p	  <	  0.001),	  ventilator	  time	  greater	  than	  48	  hours	  (RR	  =	  2.88,	  CI	  =	  
1.07	  -­‐	  7.74,	  p	  =	  0.001),	  unplanned	  intubation	  (RR	  =	  2.45,	  CI	  =	  1.21	  -­‐	  5.01,	  p	  <	  0.001),	  
renal	  insufficiency	  (RR	  =	  3.03,	  CI	  =	  1.48	  -­‐	  6.19,	  p	  <	  0.001),	  return	  to	  the	  operating	  room	  
(RR	  =	  1.51,	  CI	  =	  1.09	  -­‐	  2.09,	  p	  <	  0.001),	  wound	  dehiscence	  (RR	  =	  2.04,	  CI	  =	  1.04	  -­‐	  3.98,	  p	  =	  
0.001),	  readmission	  (RR	  =	  1.65,	  CI	  =	  1.35	  -­‐	  2.01,	  p	  <	  0.001),	  pneumonia	  (RR	  =	  2.47,	  CI	  =	  
1.48	  -­‐	  4.12,	  p	  <	  0.001),	  urinary	  tract	  infection	  (RR	  =	  1.53,	  CI	  =	  1.05	  -­‐	  2.20,	  p	  <	  0.001),	  and	  
extended	  length	  of	  stay	  (RR	  =	  1.99,	  CI	  =	  1.72	  -­‐	  2.31,	  p	  <	  0.001).	  	  These	  results	  are	  shown	  
in	  Table	  2	  and	  they	  are	  represented	  graphically	  in	  a	  forest	  plot	  in	  Figure	  2.	  	  	  
	  
Of	  note,	  not	  only	  were	  many	  more	  adverse	  events	  associated	  with	  IDDM	  than	  with	  
NIDDM,	  the	  relative	  risks	  of	  MI	  and	  extended	  LOS	  were	  greater	  for	  patients	  with	  IDDM	  
than	  for	  patients	  with	  NIDDM	  (MI:	  RR	  =	  2.71	  versus	  1.67,	  respectively,	  and	  extended	  
LOS:	  RR	  =	  1.99	  versus	  1.42).	  
	  







It	  is	  generally	  accepted	  that	  DM	  is	  a	  risk	  factor	  for	  increased	  rates	  of	  complications	  
following	  TKA.4,6,7,35,39-­‐42,46-­‐53,55-­‐57,69	  	  Despite	  the	  prevalence	  of	  DM	  and	  the	  heterogeneity	  
among	  patients	  with	  DM,	  many	  of	  these	  prior	  studies	  did	  not	  distinguish	  between	  
identifiable	  subpopulations	  of	  patients	  with	  DM.	  	  Careful	  classification	  of	  patients	  with	  
DM	  could	  identify	  groups	  that	  are	  at	  particular	  risk	  for	  adverse	  events	  in	  the	  
perioperative	  period,	  and	  this	  information	  could	  be	  useful	  for	  postoperative	  
expectations	  and	  refinement	  of	  risk	  stratification.	  
	  
This	  study	  identified	  a	  large	  population	  that	  underwent	  TKA	  and	  found	  that	  patients	  
who	  use	  insulin	  in	  the	  management	  of	  DM	  are	  at	  greater	  risk	  for	  perioperative	  adverse	  
events	  independent	  of	  demographics	  and	  comorbid	  factors.	  	  The	  results	  of	  this	  study	  
are	  consistent	  with	  recent	  research	  that	  shows	  that	  patients	  with	  IDDM	  are	  at	  a	  greater	  
risk	  for	  medical	  complications	  when	  undergoing	  TJA,57	  but	  this	  study	  shows	  that	  insulin	  
dependence	  is	  also	  an	  independent	  risk	  factor	  for	  many	  other	  adverse	  events	  including	  
sepsis	  or	  septic	  shock,	  MI,	  renal	  failure,	  ventilator	  time	  greater	  than	  48	  hours,	  
unplanned	  intubation,	  renal	  insufficiency,	  return	  to	  the	  operating	  room,	  wound	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dehiscence,	  readmission,	  pneumonia,	  urinary	  tract	  infection,	  and	  extended	  length	  of	  
stay.	  
	  
This	  study	  has	  several	  limitations.	  	  In	  our	  analysis	  patients	  with	  IDDM,	  NIDDM,	  and	  
without	  DM	  are	  defined	  by	  their	  use	  of	  insulin	  or	  other	  medications.	  	  For	  this	  reason,	  it	  
is	  possible	  that	  some	  patients	  who	  actually	  have	  DM	  are	  included	  in	  the	  group	  without	  
DM	  if	  those	  patients	  are	  not	  using	  any	  medications	  to	  control	  hyperglycemia.	  	  
Furthermore,	  there	  is	  an	  increasing	  awareness	  that	  lowering	  average	  blood	  glucose	  in	  
the	  3	  months	  prior	  to	  surgery	  may	  be	  important	  to	  prevent	  postoperative	  morbidity	  and	  
mortality.61	  	  Average	  blood	  glucose	  is	  often	  monitored	  by	  glycated	  hemoglobin	  (HbA1c)	  
level,	  but	  because	  the	  ACS	  NSQIP	  database	  does	  not	  record	  HbA1c	  level	  the	  average	  
blood	  glucose	  level	  of	  individuals	  in	  this	  cohort	  before	  surgery	  or	  in	  the	  postoperative	  
period	  could	  not	  be	  evaluated,	  and	  this	  is	  a	  limitation	  of	  this	  study.	  	  Because	  the	  
multivariate	  analyses	  could	  not	  be	  adjusted	  for	  HbA1c	  level,	  it	  is	  not	  possible	  to	  
determine	  whether	  insulin	  dependence	  is	  a	  risk	  factor	  independent	  of	  average	  blood	  
glucose	  level.	  	  Likewise,	  studies	  have	  also	  shown	  that	  perioperative	  glycemic	  control	  is	  
an	  important	  risk	  factor	  for	  adverse	  events,80	  but	  perioperative	  blood	  glucose	  levels	  are	  
not	  recorded	  in	  the	  ACS	  NSQIP	  database	  either,	  and	  for	  this	  reason	  it	  is	  also	  not	  possible	  
for	  this	  study	  to	  determine	  if	  insulin	  dependence	  is	  a	  risk	  factor	  independent	  of	  
perioperative	  blood	  glucose	  levels.	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It	  should	  be	  mentioned	  that	  the	  mechanism	  of	  the	  association	  between	  IDDM	  and	  the	  
risk	  of	  adverse	  events	  is	  not	  known.	  	  The	  results	  of	  this	  study	  should	  not	  be	  interpreted	  
to	  imply	  that	  insulin	  use	  itself	  is	  directly	  associated	  with	  adverse	  events.	  	  For	  example,	  
perioperative	  insulin	  regimens	  should	  not	  be	  modified	  based	  on	  the	  results	  of	  this	  study.	  	  
It	  is	  possible	  that	  patients	  with	  IDDM	  more	  often	  have	  advanced	  DM	  relative	  to	  patients	  
with	  NIDDM,	  and	  this	  may	  account	  for	  some	  of	  the	  differences	  in	  the	  relative	  risks	  of	  
adverse	  events,	  but	  advanced	  DM	  may	  not	  account	  for	  all	  of	  the	  differences,	  and	  this	  
should	  be	  an	  area	  of	  future	  research.	  
	  
Despite	  the	  above	  limitations,	  this	  study	  of	  postoperative	  adverse	  events	  in	  114,102	  
patients	  in	  a	  prospectively-­‐collected	  national	  database	  who	  underwent	  TKA	  is	  unique	  in	  
its	  size	  and	  scope.	  	  For	  the	  first	  time	  this	  study	  shows	  that	  insulin	  dependence	  is	  an	  
independent	  risk	  factor	  for	  12	  adverse	  events	  while	  patients	  with	  NIDDM	  are	  at	  
increased	  risk	  for	  only	  2	  of	  these	  adverse	  events	  (MI	  and	  extended	  LOS)	  relative	  to	  
patients	  without	  DM.	  	  Absolute	  risks	  of	  these	  adverse	  events	  given	  patient	  
demographics	  and	  comorbidities	  can	  be	  found	  using	  the	  ACS	  NSQIP	  surgical	  risk	  
calculator	  at	  (http://riskcalculator.facs.org).59	  	  This	  study	  controlled	  for	  those	  
demographics	  and	  comorbidities	  to	  show	  that	  patients	  with	  IDDM	  had	  increased	  
relative	  risks	  of	  many	  more	  adverse	  events	  than	  patients	  with	  NIDDM	  relative	  to	  







This	  study	  found	  that	  insulin	  dependence	  is	  an	  independent	  risk	  factor	  for	  adverse	  
events	  after	  TKA.	  	  Already	  1	  in	  5	  patients	  who	  will	  undergo	  total	  joint	  arthroplasty	  in	  the	  
US	  has	  DM.	  	  As	  the	  prevalence	  of	  DM	  and	  the	  frequency	  of	  TKA	  both	  increase,	  the	  
population	  of	  patients	  who	  will	  be	  candidates	  for	  TKA	  is	  also	  likely	  to	  increase.	  	  For	  these	  
reasons,	  orthopaedic	  surgeons	  should	  be	  aware	  of	  the	  utility	  of	  insulin	  dependence	  as	  a	  
predictor	  of	  adverse	  events.	  	  Although	  average	  glucose	  level	  as	  measured	  by	  HbA1c	  and	  
perioperative	  blood	  glucose	  level	  are	  well	  recognized	  risk	  factors	  for	  adverse	  events,60	  
the	  association	  between	  insulin	  dependence	  and	  the	  risk	  for	  adverse	  events	  has	  not	  
been	  well	  appreciated.	  	  This	  information	  will	  be	  useful	  for	  patient	  selection,	  
preoperative	  risk	  stratification,	  and	  postoperative	  management.	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CONCLUSION	  TO	  CHAPTERS	  
	  
Although	  insulin	  dependence	  has	  been	  a	  known	  predictor	  of	  cardiac	  risk	  during	  major	  
noncardiac	  surgery	  since	  1999,58	  many	  of	  the	  positive	  findings	  reported	  in	  the	  chapters	  
above	  have	  never	  before	  been	  reported	  in	  the	  orthopaedic	  literature.	  	  For	  this	  reason	  it	  
is	  important	  to	  note	  that	  our	  negative	  findings	  are	  supported	  by	  similar	  findings	  in	  the	  
orthopaedic	  literature.	  	  Of	  note,	  this	  study	  found	  no	  association	  between	  IDDM	  or	  
NIDDM	  and	  thrombotic	  events	  in	  the	  THA	  population	  of	  71,733	  or	  the	  TKA	  population	  of	  
114,102.	  	  Similarly,	  a	  prior	  systematic	  search	  of	  PubMed,	  Cochrane,	  MEDLINE,	  and	  the	  
American	  Academy	  of	  Orthopaedic	  Surgeons	  indexes	  found	  18,075	  cases	  of	  venous	  
thromboembolism	  (VTE)	  among	  1,723,350	  patients	  who	  underwent	  either	  THA	  or	  TKA	  
and	  found	  that	  although	  known	  varicose	  veins,	  comorbid	  congestive	  heart	  failure,	  and	  a	  
known	  positive	  history	  of	  VTE	  were	  associated	  with	  perioperative	  VTE,	  previously	  
diagnosed	  DM	  had	  no	  significant	  association	  with	  VTE	  after	  THA	  or	  TKA.82	  	  Another	  
study	  using	  the	  TJA	  population	  in	  the	  Nationwide	  Inpatient	  Sample	  from	  2003	  to	  2009	  
found	  no	  increased	  odds	  of	  VTE	  in	  patients	  with	  DM	  who	  underwent	  THA	  or	  TKA	  after	  
controlling	  for	  coronary	  artery	  disease,	  congestive	  heart	  failure,	  chronic	  obstructive	  
pulmonary	  disease,	  and	  cerebrovascular	  disease.83	  	  In	  fact,	  one	  study	  of	  23,326	  patients	  
at	  Veterans	  Affairs	  hospitals	  who	  underwent	  TJA	  between	  2002	  and	  2009	  found	  that	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patients	  with	  DM	  had	  a	  lesser	  risk	  of	  VTE	  than	  patients	  without	  DM.84	  	  The	  negative	  
findings	  of	  this	  study	  are	  supported	  by	  similar	  negative	  findings	  in	  the	  literature,	  and	  
this	  suggests	  that	  the	  positive	  findings	  of	  this	  study	  may	  be	  externally	  valid.	  	  	  
	  
It	  is	  also	  important	  to	  note	  that	  this	  study	  is	  not	  the	  first	  to	  investigate	  the	  relationship	  
between	  IDDM	  and	  adverse	  events	  after	  TJA.	  	  Briefly,	  DM	  is	  defined	  by	  a	  fasting	  glucose	  
greater	  than	  or	  equal	  to	  126mg/dl,	  or	  a	  2	  hour	  glucose	  tolerance	  test	  greater	  than	  
200mg/dl,	  or	  a	  random	  glucose	  greater	  than	  200mg/dl,	  or	  a	  HbA1c	  level	  greater	  than	  
6.5%.31	  	  The	  pathogenesis	  of	  DM	  type	  1	  is	  related	  to	  autoimmune	  destruction	  of	  the	  
insulin	  secreting	  beta	  cells	  of	  the	  pancreas,32	  and	  the	  pathogenesis	  of	  DM	  type	  2	  is	  
related	  to	  acquired	  insulin	  resistance.	  	  Patients	  with	  DM	  type	  1	  are	  always	  insulin	  
dependent	  while	  patients	  with	  DM	  type	  2	  can	  be	  managed	  with	  diet	  and	  lifestyle	  
modifications	  or	  oral	  hypoglycemic	  agents	  initially,	  but	  patients	  with	  recalcitrant	  DM	  
type	  2	  may	  become	  insulin	  dependent.32,33	  	  Although	  DM	  is	  in	  this	  way	  recognized	  to	  be	  
a	  heterogeneous	  group	  of	  metabolic	  disorders,	  very	  few	  prior	  studies	  of	  adverse	  events	  
after	  TJA	  distinguished	  between	  these	  identifiable	  subpopulations	  of	  patients	  with	  DM.	  	  
	  
One	  prior	  study	  from	  the	  Mayo	  Clinic	  in	  Rochester,	  MN	  found	  an	  association	  between	  
insulin	  use	  and	  periprosthetic	  joint	  infection	  in	  TJA	  patients	  when	  controlling	  for	  age	  and	  
gender,	  but	  this	  association	  did	  not	  remain	  when	  also	  controlling	  for	  BMI	  and	  
comorbidity	  burden.56	  	  A	  follow-­‐up	  study	  of	  all	  morbidly	  obese	  patients	  (BMI	  >	  40	  
kg/m2)	  who	  underwent	  primary	  TKA	  between	  1995	  and	  2011	  with	  a	  minimum	  of	  two	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years	  of	  follow-­‐up	  found	  that	  patients	  with	  DM	  type	  2	  had	  similar	  outcomes	  when	  
compared	  to	  patients	  without	  DM,	  but	  this	  study	  also	  found	  that	  those	  patients	  with	  
DM	  type	  2	  and	  insulin	  dependence	  had	  increased	  risks	  of	  reoperation,	  revision,	  
periprosthetic	  joint	  infection,	  and	  decreased	  10-­‐year	  implant	  survivorship	  when	  
compared	  to	  patients	  without	  DM.53	  	  These	  findings	  suggests	  that	  insulin	  dependence	  
may	  be	  a	  stronger	  predictor	  of	  adverse	  events	  than	  DM	  alone.	  	  Other	  than	  
periprosthetic	  joint	  infection,	  however,	  that	  study	  did	  not	  investigate	  the	  rates	  of	  the	  16	  
other	  adverse	  events	  that	  this	  study	  investigated.	  
	  
A	  secondary	  analysis	  of	  an	  observational	  study	  of	  8,055	  patients	  in	  Denmark	  also	  found	  
that	  patients	  treated	  with	  insulin	  were	  at	  an	  increased	  risk	  for	  a	  composite	  measure	  of	  
“diabetes-­‐related	  morbidity”	  after	  TJA,	  but	  the	  authors	  of	  that	  study	  cautioned	  against	  
drawing	  conclusions	  from	  that	  secondary	  analysis.55	  	  In	  that	  observational	  study,	  890	  
patients	  with	  DM	  type	  2	  who	  underwent	  TJA	  were	  matched	  with	  7,165	  patients	  without	  
DM.	  	  That	  study	  used	  the	  Danish	  National	  Database	  of	  Reimbursed	  Prescriptions	  to	  
stratify	  patients	  with	  DM	  by	  treatment	  regimen	  (insulin,	  oral	  antihyperglycemic	  agents	  
only,	  and	  diet	  only).	  	  The	  Danish	  National	  Health	  Registry	  was	  used	  to	  track	  adverse	  
events	  including	  readmission	  and	  extended	  LOS.	  	  The	  study	  found	  that	  only	  the	  patients	  
with	  DM	  type	  2	  treated	  with	  insulin	  were	  at	  an	  increased	  risk	  of	  postoperative	  
morbidity.	  	  	  These	  patients	  were	  at	  an	  increased	  risk	  for	  the	  composite	  outcome	  of	  
“diabetes-­‐related	  morbidity”	  which	  was	  defined	  as	  any	  one	  of	  cardiac	  arrhythmia,	  acute	  
congestive	  heart	  failure,	  myocardial	  infarction,	  periprosthetic	  or	  wound	  infections,	  renal	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insufficiency,	  stroke	  or	  transient	  ischemic	  attack,	  pneumonia,	  sepsis,	  LOS	  greater	  than	  4	  
days	  caused	  by	  urinary	  tract	  infection	  or	  dysregulated	  blood	  glucose,	  or	  any	  other	  
infection	  that	  led	  to	  readmission.55	  	  In	  contrast	  to	  this	  composite	  outcome,	  our	  analysis	  
investigates	  each	  of	  these	  adverse	  events	  individually.	  
	  
In	  a	  similar	  manner,	  a	  previous	  study	  using	  an	  ACS	  NSQIP	  sample	  less	  than	  one	  quarter	  
the	  size	  of	  this	  study	  found	  an	  association	  between	  IDDM	  and	  a	  composite	  of	  “medical	  
complications,”57	  but	  that	  study	  did	  not	  isolate	  the	  THA	  or	  TKA	  populations	  and	  did	  not	  
find	  an	  association	  between	  IDDM	  and	  any	  particular	  adverse	  events.	  
	  
This	  study	  is	  not	  without	  limitations.	  	  The	  reliability	  of	  findings	  that	  are	  based	  on	  
database	  studies	  is	  controversial.	  	  A	  recent	  study	  compared	  the	  patient	  characteristics	  
of	  the	  populations	  that	  underwent	  total	  hip	  arthroplasty	  for	  hip	  osteoarthritis	  in	  two	  
commonly	  used	  databases	  and	  also	  compared	  the	  adverse	  event	  rates	  that	  these	  
databases	  reported.	  	  That	  study	  found	  differences	  between	  demographic	  characteristics	  
and	  outcomes	  between	  databases	  and	  concluded	  that	  large	  databases	  can	  have	  limited	  
reliability	  and	  should	  be	  interpreted	  with	  caution.78	  	  That	  study	  compared	  the	  National	  
Hospital	  Discharge	  Survey	  (NHDS)	  database	  to	  the	  Nationwide	  Inpatient	  Sample	  (NIS)	  
database.	  	  This	  study,	  however,	  uses	  the	  ACS	  NSQIP	  database.	  	  The	  ACS	  NSQIP	  database	  
differs	  significantly	  from	  NHDS	  and	  NIS	  in	  methods	  of	  data	  collection	  and	  follow-­‐up.	  	  In	  
contrast	  to	  administrative	  databases	  that	  are	  based	  on	  reimbursement	  claims	  and	  have	  
been	  shown	  to	  be	  limited,62	  inconsistent,63	  and	  fraught	  with	  errors,64	  ACS	  NSQIP	  data	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are	  chart-­‐abstracted	  and	  prospectively	  collected,	  and	  high-­‐quality	  data	  is	  ensured	  by	  
routine	  auditing.	  	  This	  is	  demonstrated	  by	  an	  agreement	  rate	  between	  clinical	  reviewers	  
of	  greater	  than	  98%.65	  	  Reliability	  and	  internal	  validity	  are	  particularly	  important	  when	  
cohort	  subpopulations	  are	  defined	  by	  clinical	  criteria,	  and	  for	  these	  reasons	  studies	  of	  
ACS	  NSQIP	  may	  more	  accurately	  reflect	  the	  real	  demographic	  characteristics	  of	  the	  
population	  under	  study	  and	  may	  more	  accurately	  reflect	  the	  real	  rate	  of	  postoperative	  
adverse	  events	  than	  studies	  that	  use	  the	  administratively-­‐coded	  NHDS	  and	  NIS	  
databases.	  
	  
Although	  the	  ACS	  NSQIP	  database	  distinguishes	  between	  IDDM	  and	  NIDDM,	  the	  
database	  lacks	  data	  concerning	  DM	  type.	  	  A	  prior	  study	  of	  NIS	  from	  1988	  to	  2003	  
studied	  the	  effect	  of	  DM	  type	  on	  the	  risk	  of	  adverse	  events.	  	  That	  study	  identified	  
65,769	  patients	  with	  DM	  who	  underwent	  TJA	  and	  compared	  the	  adverse	  event	  rates	  of	  
those	  with	  DM	  type	  1	  (8,728	  patients)	  to	  those	  with	  DM	  type	  2	  (57,041	  patients).	  	  That	  
study	  found	  that	  patients	  with	  DM	  type	  1	  were	  at	  greater	  risk	  for	  death,	  myocardial	  
infarction,	  pneumonia,	  postoperative	  hemorrhage,	  wound	  infection,	  and	  urinary	  tract	  
infection.54	  	  And	  patients	  with	  DM	  type	  1	  were	  also	  found	  to	  have	  longer	  LOS	  and	  
greater	  inflation-­‐adjusted	  costs	  of	  surgery.54	  
	  
Noting	  that	  insulin	  is	  essential	  for	  the	  pharmacological	  management	  of	  DM	  type	  1	  and	  
considering	  the	  findings	  of	  the	  previously	  discussed	  study	  from	  the	  Mayo	  Clinic,53	  it	  is	  
certain	  that	  the	  effects	  of	  DM	  type	  and	  insulin	  dependence	  are	  confounding.	  	  The	  ACS	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NSQIP	  database,	  however,	  does	  not	  record	  DM	  type.	  	  For	  that	  reason,	  although	  DM	  type	  
is	  clearly	  related	  to	  perioperative	  adverse	  event	  rates,	  this	  study	  could	  not	  control	  for	  
DM	  type	  and	  this	  study	  could	  not	  determine	  if	  the	  increased	  relatives	  risk	  of	  insulin	  
dependence	  were	  independent	  of	  DM	  type.	  
	  
Similarly,	  although	  ACS	  NSQIP	  does	  record	  some	  pre-­‐operative	  lab	  values,	  it	  does	  not	  
record	  preoperative	  HbA1c	  level.	  	  Whether	  or	  not	  HbA1c	  level	  should	  be	  considered	  
during	  patient	  optimization	  for	  elective	  surgery	  is	  controversial.	  	  While	  some	  authors	  
suggest	  that	  HbA1c	  levels	  are	  not	  reliable	  for	  predicting	  the	  risk	  of	  infection	  after	  TJA,41	  
other	  authors	  suggest	  that	  perioperative	  glycemic	  control80	  or	  correction	  of	  elevated	  
HbA1c	  over	  several	  preoperative	  months61,79	  could	  decrease	  perioperative	  complication	  
rates,	  and	  still	  other	  authors	  note	  that	  the	  linear	  relationship	  observed	  between	  adverse	  
event	  rates	  and	  HbA1c	  suggests	  that	  efforts	  to	  optimize	  preoperative	  HbA1c	  should	  be	  
revised.79,85	  	  Regardless	  of	  the	  controversy,	  this	  study	  could	  not	  control	  for	  preoperative	  
HbA1c	  level	  and	  this	  study	  could	  not	  determine	  if	  the	  increased	  relatives	  risk	  of	  insulin	  
dependence	  were	  independent	  of	  HbA1c	  level.	  
	  	  
These	  limitations	  suggest	  further	  areas	  of	  research	  and	  they	  pose	  questions	  that	  future	  
investigations	  may	  answer.	  	  This	  study	  found	  that	  patients	  with	  IDDM	  had	  increased	  
risks	  for	  many	  perioperative	  adverse	  events	  relative	  the	  patients	  without	  DM.	  	  This	  
study	  also	  found	  that	  patients	  with	  NIDDM	  did	  not	  share	  many	  of	  these	  risks.	  	  These	  
findings	  should	  be	  interpreted	  with	  caution.	  	  Identifying	  populations	  that	  are	  at	  greater	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risk	  for	  particular	  adverse	  events	  in	  the	  perioperative	  period	  is	  important,	  and	  although	  
this	  study	  has	  shown	  that	  simply	  noting	  insulin	  dependence	  can	  herald	  vastly	  different	  
outcomes	  for	  patients,	  the	  rates	  of	  the	  adverse	  events	  studied	  are	  relatively	  low	  for	  
both	  patients	  with	  IDDM	  and	  patients	  with	  NIDDM.	  This	  information	  will	  be	  useful	  for	  
patient	  counseling	  and	  expectations,	  preoperative	  risk	  stratification,	  and	  postoperative	  
management.	  	  Identifying	  particular	  adverse	  events	  will	  encourage	  the	  implementation	  
of	  appropriate	  preventative	  and	  monitoring	  measures	  for	  at-­‐risk	  patients,	  and	  
substantiating	  these	  greater	  risks	  and	  costs	  of	  providing	  care	  to	  particular	  
subpopulations	  will	  contribute	  to	  efforts	  to	  ameliorate	  potential	  disparities	  in	  the	  
provision	  of	  TJA.	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